63 results on '"Sauter, R."'
Search Results
2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
- Author
-
Becker M, Graf N, Sauter R, Curram J, Denton C, Khanna D, Pena J, Pope J, Distler O, Matucci-Cerinic M, Guiducci S, Walker U, Jaeger V, Bannert B, Lapadula G, Becvarare R, Cutolo M, Valentini G, Siegert E, Rednic S, Allanore Y, Montecucco C, Carreira P, Novak S, Czirjak L, Varju C, Chizzolini C, Allai D, Kucharz E, Cozzi F, Rozman B, Mallia C, Gabrielli A, Bancel D, Airo P, Hesselstrand R, Martinovic D, Balbir-Gurman A, Braun-Moscovici Y, Hunzelmann N, Pellerito R, Caramaschi P, Black C, Damjanov N, Henes J, Santamaria V, Heitmann S, Seidel M, Da Silva J, Stamenkovic B, Selmi C, Tikly M, Denisov L, Muller-Ladner U, Engelhart M, Hachulla E, Riccieri V, Ionescu R, Mihai C, Sunderkotter C, Kuhn A, Schett G, Distler J, Meroni P, Ingegnoli F, Mouthon L, De Keyser F, Smith V, Cantatore F, Corrado A, Ullman S, Iversen L, Pozzi M, Eyerich K, Hein R, Knott E, Wiland P, Szmyrka-Kaczmarek M, Sokolik R, Morgiel E, Madej M, Alegre-Sancho J, Krummel-Lorenz B, Saar P, Aringer M, Gunther C, Anne E, Westhovens R, De Langhe E, Lenaerts J, Anic B, Baresic M, Mayer M, Uprus M, Otsa K, Yavuz S, Radominski S, Muller C, Azevedo V, Popa S, Zenone T, Stebbings S, Highton J, Mathieu A, Vacca A, Stamp L, Chapman P, O'Donnell J, Solanki K, Doube A, Veale D, O'Rourke M, Loyo E, Li M, Rosato E, Amoroso A, Gigante A, Oksel F, Yargucu F, Tanaseanu C, Popescu M, Dumitrascu A, Tiglea I, Foti R, Visalli E, Benenati A, Amato G, Ancuta C, Chirieac R, Villiger P, Adler S, Dan D, Lefebvre P, Rubio S, Exposito M, Sibilia J, Chatelus E, Gottenberg J, Chifflot H, Litinsky I, Del Galdo F, Venalis A, Saketkoo L, Lasky J, Kerzberg E, Montoya F, Cosentino V, Limonta M, Brucato A, Lupi E, Spertini F, Ribi C, Buss G, Martin T, Guffroy A, Poindron V, Chung L, Schmeiser T, Zebryk P, Riso N, Riemekasten G, Rezus E, Puttini P, and EUSTAR Collaborators
- Abstract
Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in systemic sclerosis (SSc). The aim of this study was to identify factors that allow enrichment of patients with these endpoints, in a population of patients from the European Scleroderma Trials and Research group database. Methods Inclusion criteria were diagnosis of diffuse SSc and follow-up over 12 +/- 3 months. Disease worsening/organ progression was fulfilled if any of the following events occurred: new renal crisis; decrease of lung or heart function; new echocardiography-suspected pulmonary hypertension or death. In total, 42 clinical parameters were chosen as predictors for the analysis by using (1) imputation of missing data on the basis of multivariate imputation and (2) least absolute shrinkage and selection operator regression. Results Of 1451 patients meeting the inclusion criteria, 706 had complete data on outcome parameters and were included in the analysis. Of the 42 outcome predictors, eight remained in the final regression model. There was substantial evidence for a strong association between disease progression and age, active digital ulcer (DU), lung fibrosis, muscle weakness and elevated C-reactive protein (CRP) level. Active DU, CRP elevation, lung fibrosis and muscle weakness were also associated with a significantly shorter time to disease progression. A bootstrap validation step with 10 000 repetitions successfully validated the model. Conclusions The use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials.
- Published
- 2019
3. Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities
- Author
-
Mulubwa, C, Hensen, B, Phiri, MM, Shanaube, K, Schaap, AJ, Floyd, S, Phiri, CR, Bwalya, C, Bond, V, Simwinga, M, Mwenge, L, Fidler, S, Hayes, R, Mwinga, A, Ayles, H, Beyer, N, Bock, P, El-Sadr, W, Cohen, M, Eshleman, S, Agyei, Y, Piwowar-Manning, E, Hoddinott, G, Donnell, D, Wilson, E, Emel, L, Noble, H, Macleod, D, Burns, D, Fraser, C, Cori, A, Sista, N, Griffith, S, Moore, A, Headen, T, White, R, Miller, E, Hargreaves, J, Hauck, K, Thomas, R, Limbada, M, Bwalya, J, Pickles, M, Sabapathy, K, Dunbar, R, Yang, B, Smith, PC, Vermund, S, Mandla, N, Makola, N, Van Deventer, A, James, A, Jennings, K, Kruger, J, Phiri, M, Kosloff, B, Kanema, S, Sauter, R, Probert, W, Kumar, R, Sakala, E, Silumesi, A, Skalland, T, Yuhas, K, National Institutes of Health, National Institute for Health Research, Department for International Development (UK) (DFI, and Medical Research Council (MRC)
- Subjects
Science & Technology ,Infectious Diseases ,Immunology ,virus diseases ,KENYA ,HPTN 071 (PopART) Study Team ,Life Sciences & Biomedicine - Abstract
Background The HPTN 071 (PopART) cluster-randomised trial provided door-to-door HIV testing services to a large proportion of individuals residing in 21 intervention communities in Zambia and South Africa from 2014 to 2017 and reached the UNAIDS first 90 target among women in Zambia, yet gaps remained among men and young adults. This cluster-randomised study nested in the HPTN 071 (PopART) trial sought to increase knowledge of HIV status across all groups by offering the choice of oral HIV self-testing in addition to routine door-to-door HIV testing services. Methods We nested this cluster-randomised trial in four HTPN 071 (PopART) intervention communities in northern Zambia. 66 zones (clusters) in these communities were randomly allocated (1:1) to either oral HIV self-testing plus routine door-to-door HIV testing services (HIV self-testing group) or the PopART standard of care of door-to-door HIV testing services alone (non- HIV self-testing group) over a 3-month period. All individuals aged 16 years or older were eligible for HIV testing. Randomisation was achieved by randomly selecting one allocation from a list of 10 000 possible allocations during a public ceremony. In HIV self-testing zones, trained lay-counsellors (known as community HIV care providers) visited households and offered eligible individuals the choice of HIV testing using HIV self-testing or routine door-to-door HIV testing services. For individuals aged 18 years or older whose partner was absent during the household visit, an HIV self-test kit could be left for secondary distribution to the absent partner. The primary outcome was knowledge of HIV status (defined as self-reporting HIV positive to the community HIV care providers or accepting an offer of HIV testing services). Outcomes were measured among households that were first visited, and individuals first enumerated as a household member during the HIV self-testing intervention period. We analysed data at the individual level using population-average logistic regression models, accounting for clustering of outcomes by zone, to estimate the effect of the intervention. This trial is registered with ClinicalTrials.gov, number NCT02994329. Findings Between Feb 1, and April 30, 2017, the community HIV care providers enumerated 13 267 eligible individuals in the HIV self-testing group and 13 706 in the non-HIV self-testing group. After intervention implementation, 9027 (68%) of 13 267 in the HIV self-testing group had knowledge of HIV status compared with 8952 (65%) of 13 706 in the non-HIV self-testing group (adjusted odds ratio 1·30, 95% CI 1·03–1·65; p=0·03). The effect differed by sex (pinteraction=0·01). Among men, knowledge of HIV status was higher in the HIV self-testing group than in the non-HIV self-testing group (3843 [60%] of 6368 vs 3571 [55%] of 6486; adjusted odds ratio 1·31, 95% CI 1·07–1·60; p=0·01). There was no evidence of a between-group difference among female participants. Interpretation Providing a choice of HIV self-testing during delivery of door-to-door HIV testing services increased knowledge of HIV status, driven by an effect among men. Lay counsellors have a vital role to play in adapting HIV self-testing interventions to local context.
- Published
- 2018
4. P4724Elevated mitral valve pressure gradient is predictive for long-term outcome after percutaneous edge-to-edge mitral valve repair (PMVR) in patients with degenerative MR, but not in functional MR
- Author
-
Patzelt, J, primary, Zhang, W, additional, Sauter, R, additional, Mezger, M, additional, Nording, H, additional, Becker, A S, additional, Rudolph, V, additional, Saad, M, additional, Eitel, I, additional, Schlensak, C, additional, Gawaz, M, additional, Boekstegers, P, additional, Schreieck, J, additional, Seizer, P, additional, and Langer, H F, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Effect of the relative shift between the electron density and temperature pedestal position on the pedestal stability in JET-ILW and comparison with JET-C
- Author
-
Stefanikova, E., Frassinetti, L., Saarelma, S., Loarte, A., Nunes, I., Garzotti, L., Lomas, P., Rimini, F., Drewelow, P., Kruezi, U., Lomanowski, B., De La Luna, E., Meneses, L., Peterka, M., Viola, B., Giroud, C., Litaudon, Maggi C., Abduallev, X., Abhangi, S., Abreu, M., Afzal, P., Aggarwal, M., Ahlgren, K. M., Ahn, T., J. H., Aho, Mantila, Aiba, L., Airila, N., Albanese, M., Aldred, R., Alegre, V., Alessi, D., Aleynikov, E., Alfier, P., Alberto, Alkseev, Allinson, A., Alper, M., Alves, B., Ambrosino, E., Ambrosino, G., Amicucci, R., Amosov, L., Andersson, Sundã©n, Angelone, E., Anghel, M., Angioni, M., Appel, C., Appelbee, L., Arena, C., Ariola, P., Arnichand, M., Arshad, H., Ash, S., Ashikawa, A., Aslanyan, N., Asunta, V., Auriemma, O., Fulvio, Austin, Avotina, Y., Axton, L., Ayres, M. D., Bacharis, C., Baciero, M., Baiã¡o, A., Bailey, D., Baker, S., Balboa, A., Balden, I., Balshaw, M., Bament, N., Banks, R., Baranov, J. W., Barnard, Y. F., Barnes, M. A., Barnes, D., Barnsley, M., Baron, Wiechec, Barrera, Orte, Baruzzo, L., Matteo, Basiuk, Bassan, V., Bastow, M., Batista, R., Batistoni, A., Baughan, P., Bauvir, R., Baylor, B., Bazylev, L., Beal, B., Beaumont, J., Beckers, P. S., Beckett, M., Becoulet, B., Bekris, A., Beldishevski, N., Bell, M., Belli, K., Bellinger, F., Belonohy, M., Ben, Ayed, Benterman, N., Bergsã¥ker, N. A., Bernardo, H., Bernert, J., Berry, M., Bertalot, M., Besliu, L., Beurskens, C., Bieg, M., Bielecki, B., Biewer, J., Bigi, T., Bã¬lkovã¡, M., Binda, P., Bisoffi, F., Bizarro, A., Bjã¶rkas, J. P. S., Blackburn, C., Blackman, J., Blackman, K., Blanchard, T. R., Blatchford, P., Bobkov, P., Boboc, V., Bodnã¡r, A., Bogar, G., Bolshakova, O., Bolzonella, I., Tommaso, Bonanomi, Bonelli, N., Boom, F., Booth, J., Borba, J., Borodin, D., Borodkina, D., Botrugno, I., Bottereau, A., Boulting, C., Bourdelle, P., Bowden, C., Bower, M., Bowman, C., Boyce, C., Boyd, T., Boyer, C., Bradshaw, H. J., Braic, J. M. A., Bravanec, V., Breizman, R., Bremond, B., Brennan, S., Breton, P. D., Brett, S., Brezinsek, A., Bright, S., Brix, M. D. J., Broeckx, M., Brombin, W., Matteo, Broså‚awski, Brown, A., Brown, D. P. D., Bruno, M., Bucalossi, E., Buch, J., Buchanan, J., Buckley, J., Budny, M. A., Bufferand, R., Bulman, H., Bulmer, M., Bunting, N., Buratti, P., Burckhart, P., Buscarino, A., Busse, A., Butler, A., Bykov, N. K., Byrne, I., Cahyna, J., Calabrã², P., Calvo, G., Camenen, I., Camp, Y., Campling, P., Cane, D. C., Cannas, J., Capel, B., Card, A. J., Cardinali, P. J., Carman, A., Carr, P., Carralero, M., Carraro, D., Carvalho, L., Carvalho, B. B., Carvalho, I., Casson, P., Castaldo, F. J., Catarino, C., Caumont, N., Causa, J., Cavazzana, F., Cave, Ayland, Cavinato, K., Cecconello, M., Ceccuzzi, M., Cecil, S., Cenedese, E., Angelo, Cesario, Challis, R., Chandler, C. D., Chandra, M., Chang, D., Chankin, C. S., Chapman, A., Chapman, I. T., Chernyshova, S. C., Chitarin, M., Giuseppe, Ciraolo, Ciric, G., Citrin, D., Clairet, J., Clark, F., Clark, E., Clarkson, M., Clatworthy, R., Clements, D., Cleverly, C., Coad, M., Coates, J. P., Cobalt, P. A., Coccorese, A., Cocilovo, V., Coda, V., Coelho, S., Coenen, R., Coffey, J. W., Colas, I., Collins, L., Conka, S., Conroy, D., Conway, S., Coombs, N., Cooper, D., Corradino, S. R., Corre, C., Corrigan, Y., Cortes, G., Coster, S., Couchman, D., Cox, A. S., Craciunescu, M. P., Cramp, T., Craven, S., Crisanti, R., Croci, F., Croft, G., Crombã©, D., Crowe, K., Cruz, R., Cseh, N., Cufar, G., Cullen, A., Curuia, A., Czarnecka, M., Dabirikhah, A., Dalgliesh, H., Dalley, P., Dankowski, S., Darrow, J., Davies, D., Davis, O., Day, W., Day, C., I. E., Bock, De, Castro, De, De La Cal, De La Luna, Masi, De, Pablos, De, J. L., Temmerman, De, Tommasi, De, Vries, De, Deakin, P., Deane, K., Degli, Agostini, Dejarnac, F., Delabie, R., Den, Harder, Dendy, N., Denis, R. O., Denner, J., Devaux, P., Devynck, S., Maio, Di, Siena, Di, Troia, Di, Dinca, C., D'Inca, P., Ding, R., Dittmar, B., Doerk, T., Doerner, H., Donnã©, R. P., Dorling, T., S. E., Dormido, Canto, Doswon, S., Douai, S., Doyle, D., Drenik, P. T., Drewelow, A., Drews, P., Duckworth, P., Dumont, P. h., Dumortier, R., Dunai, P., Dunne, D., Äžuran, M., Durodiã©, I., Dutta, F., Duval, P., Dux, B. P., Dylst, R., Dzysiuk, K., Edappala, N., Edmond, P. V., Edwards, J., Edwards, A. M., Eich, J., Ekedahl, T. h., Jorf, El, Elsmore, R., Enachescu, C. G., Ericsson, M., Eriksson, G., Eriksson, F., Eriksson, J., Esposito, L. G., Esquembri, B., Esser, S., Esteve, H. G., Evans, D., Evans, B., Evison, G. E., Ewart, G., Fagan, G. D., Faitsch, D., Falie, M., Fanni, D., Fasoli, A., Faustin, A., Fawlk, J. M., Fazendeiro, N., Fedorczak, L., Felton, N., Fenton, R. C., Fernades, K., Fernandes, A., Ferreira, H., Fessey, J., Fã©vrier, J. A., Ficker, O., Field, O., Fietz, A., Figueiredo, S., Figueiredo, A., Fil, J., Finburg, A., Firdaouss, P., Fischer, M., Fittill, U., Fitzgerald, L., Flammini, M., Flanagan, D., Fleming, J., Flinders, C., Fonnesu, K., Fontdecaba, N., Formisano, J. M., Forsythe, A., Fortuna, L., Fortuna, Zalesna, Fortune, E., Foster, M., Franke, S., Franklin, T., Frasca, T., Frassinetti, M., Freisinger, L., Fresa, M., Frigione, R., Fuchs, D., Fuller, V., Futatani, D., Fyvie, S., Gã¡l, J., Galassi, K., Gaå‚azka, D., Galdon, Quiroga, Gallagher, J., Gallart, J., Galvã¡o, D., Gao, R., Gao, X., Garcia, Y., Garcia, Carrasco, Garcã¬a, Muã±oz, Gardarein, M., Garzotti, J. L., Gaudio, L., Gauthier, P., Gear, E., Gee, D. F., Geiger, S. J., Gelfusa, B., Gerasimov, M., Gervasini, S., Gethins, G., Ghani, M., Ghate, Z., Gherendi, M., Giacalone, M., Giacomelli, J. C., Gibson, L., Giegerich, C. S., Gil, T., Gil, C., Gilligan, L., Gin, S., Giovannozzi, D., Girardo, E., Giroud, J. B., Giruzzi, C., Gerardo, Glã¶ggler, Godwin, S., Goff, J., Gohil, J., Goloborod'Ko, P., Gomes, V., Goncalves, R., Goniche, B., Goodliffe, M., Goodyear, M., Gorini, A., Gosk, G., Goulding, M., Goussarov, R., Gowland, A., Graham, R., Graham, B., Graves, M. E., Grazier, J. P., Grazier, N., Green, P., Greuner, N. R., Grierson, H., Griph, B., Grisolia, F. S., Grist, C., Groth, D., Grove, M., Grundy, R., Grzonka, C. N., Guard, J., Guã©rard, D., Guillemaut, C., Guirlet, C., Gurl, R., Utoh, C., Hackett, H. H., Hacquin, L. J., Hagar, S., Hager, A., Hakola, R., Halitovs, A., Hall, M., S. J., Hallworth, Cook, S. P., Hamlyn, Harris, Hammond, C., Harrington, K., Harrison, C., Harting, J., Hasenbeck, D., Hatano, F., Hatch, Y., Haupt, D. R., Hawes, T. D. V., Hawkes, J., Hawkins, N. C., Hawkins, J., Haydon, P., Hayter, P. W., Hazel, N., Heesterman, S., Heinola, P. J. L., Hellesen, K., Hellsten, C., Helou, T., Hemming, W., Hender, O. N., Henderson, T. C., Henderson, M., Henriques, S. S., Hepple, R., Hermon, D., Hertout, G., Hidalgo, P., Highcock, C., Hill, E. G., Hillairet, M., Hillesheim, J., Hillis, J., Hizanidis, D., Hjalmarsson, K., Hobirk, A., Hodille, J., Hogben, E., Hogeweij, C. H. A., Hollingsworth, G. M. D., Hollis, A., Homfray, S., Horã¡äek, D. A., Hornung, J., Horton, G., Horton, A. R., Horvath, L. D., Hotchin, L., Hough, S. P., Howarth, M. R., Hubbard, P. J., Huber, A., Huddleston, V., Hughes, T. M., Huijsmans, M., Hunter, G. T. A., Huynh, C. L., Hynes, P., Iglesias, A. M., Imazawa, D., Imbeaux, N., Imrã¬å¡ek, F., Incelli, M., Innocente, M., Irishkin, P., Ivanova, Stanik, Jachmich, I., Jacobsen, S., Jacquet, A. S., Jansons, P., Jardin, J., Jã¤rvinen, A., Jaulmes, A., Jednorã³g, F., Jenkins, S., Jeong, I., Jepu, C., Joffrin, I., Johnson, E., Johnson, R., Johnston, T., Jane, Joita, Jones, L., Jones, G., Hoshino, T. T. C., Kallenbach, K. K., Kamiya, A., Kaniewski, K., Kantor, J., Kappatou, A., Karhunen, A., Karkinsky, J., Karnowska, D., Kaufman, I., Kaveney, M., Kazakov, G., Kazantzidis, Y., Keeling, V., Keenan, D. L., Keep, T., Kempenaars, J., Kennedy, M., Kenny, C., Kent, D., Kent, J., Khilkevich, O. N., Kim, E., Kim, H. T., Kinch, H. S., King, A., King, C., King, D., Kinna, R. F., Kiptily, D. J., Kirk, V., Kirov, A., Kirschner, K., Kizane, A., Klepper, G., Klix, C., Knight, A., Knipe, P., Knott, S. J., Kobuchi, S., Kã¶chl, T., Kocsis, F., Kodeli, G., Kogan, I., Kogut, L., Koivuranta, D., Kominis, S., Kã¶ppen, Y., Kos, M., Koskela, B., Koslowski, T., Koubiti, H. R., Kovari, M., Kowalska, Strzè©ciwilk, Krasilnikov, E., Krasilnikov, A., Krawczyk, V., Kresina, N., Krieger, M., Krivska, K., Kruezi, A., Ksiaå¼ek, U., Kukushkin, I., Kundu, A., Kurki, Suonio, Kwak, T., Kwiatkowski, S., Kwon, R., Laguardia, O. J., Lahtinen, L., Laing, A., Lam, A., Lambertz, N., Lane, H. T., Lang, C., Lanthaler, P. T., Lapins, S., Lasa, J., Last, A., Åaszyå„ska, J. R., Lawless, E., Lawson, R., Lawson, A., Lazaros, K. D., Lazzaro, A., Leddy, E., Lee, J., Lefebvre, S., Leggate, X., Lehmann, H. J., Lehnen, J., Leichtle, M., Leichuer, D., Leipold, P., Lengar, F., Lennholm, I., Lerche, M., Lescinskis, E., Lesnoj, A., Letellier, S., Leyland, E., Leysen, M., Li, W., Liang, L., Likonen, Y., Linke, J., Linsmeier, J., Lipschultz, C. h., Liu, B., Liu, G., Schiavo, Lo, Loarer, V. P., Loarte, T., Lobel, A., Lomanowski, R. C., Lomas, B., Lã¶nnroth, P. J., Lã³pez, J., J. M., Lã³pez, Razola, Lorenzini, J., Losada, R., Lovell, U., Loving, J. J., Lowry, A. B., Luce, C., Lucock, T., Lukin, R. M. A., Luna, A., Lungaroni, C., Lungu, M., Lungu, C. P., Lunniss, M., Lupelli, A., Lyssoivan, I., Macdonald, A., Macheta, N., Maczewa, P., Magesh, K., Maget, B., Maggi, P., Maier, C., Mailloux, H., Makkonen, J., Makwana, T., Malaquias, R., Malizia, A., Manas, A., Manning, P., Manso, A., Mantica, M. E., Mantsinen, P., Manzanares, M., Maquet, A., Marandet, P. h., Marcenko, Y., Marchetto, N., Marchuk, C., Marinelli, O., Marinucci, M., Markoviä, M., Marocco, T., Marot, D., Marren, L., Marshal, C. A., Martin, R., Martin, A., Martìn De Aguilera, Martã¬nez, A., F. J., Martã¬n, Solã¬s, Martynova, J. R., Maruyama, Y., Masiello, S., Maslov, A., Matejcik, M., Mattei, S., Matthews, M., Maviglia, G. F., Mayer, F., Mayoral, M., M. L., May, Smith, Mazon, T., Mazzotta, D., Mcadams, C., Mccarthy, R., Mcclements, P. J., Mccormack, K. G., Mccullen, O., Mcdonald, P. A., Mcintosh, D., Mckean, S., Mckehon, R., Meadows, J., Meakins, R. C., Medina, A., Medland, F., Medley, M., Meigh, S., Meigs, S., Meisl, A. G., Meitner, G., Meneses, S., Menmuir, L., Mergia, S., Merrigan, K., Mertens, I. R., Meshchaninov, P. h., Messiaen, S., Meyer, A., Mianowski, H., Michling, S., Middleton, Gear, Miettunen, D., Militello, J., Militello, Asp, Miloshevsky, E., Mink, G., Minucci, F., Miyoshi, S., Mlynã¡å™, Y., Molina, J., Monakhov, D., Moneti, I., Mooney, M., Moradi, R., Mordijck, S., Moreira, S., Moreno, L., Moro, R., Morris, F., Morris, A. W., Moser, J., Mosher, L., Moulton, S., Murari, D., Muraro, A., Murphy, A., Asakura, S., N. N., Na, Nabais, Y. S., Naish, F., Nakano, R., Nardon, T., Naulin, E., Nave, V., Nedzelski, M. F. F., Nemtsev, I., Nespoli, G., Neto, F., Neu, A., Neverov, R., Newman, V. S., Nicholls, M., Nicolas, K. J., Nielsen, T., Nielsen, A. H., Nilsson, P., Nishijima, E., Noble, D., Nocente, C., Nodwell, M., Nordlund, D., Nordman, K., Nouailletas, H., Nunes, R., Oberkofler, I., Odupitan, M., Ogawa, T., O'Gorman, M. T., Okabayashi, T., Olney, M., Omolayo, R., O'Mullane, O., Ongena, M., Orsitto, J., Orszagh, F., Oswuigwe, J., Otin, B. I., Owen, R., Paccagnella, A., Pace, R., Pacella, N., Packer, D., Page, L. W., Pajuste, A., Palazzo, E., Pamela, S., Panja, S., Papp, S., Paprok, P., Parail, R., Park, V., Parra, Diaz, Parsons, F., Pasqualotto, M., Patel, R., Pathak, A., Paton, S., Patten, D., Pau, H., Pawelec, A., Paz, Soldan, Peackoc, C., Pearson, A., Pehkonen, I. J., Peluso, S. P., Penot, E., Pereira, C., Pereira, A., Pereira, Puglia, P. P., Perez Von Thun, Peruzzo, C., Peschanyi, S., Peterka, S., Petersson, M., Petravich, P., Petre, G., Petrella, A., Petrå¾ilka, N., Peysson, V., Pfefferlã©, Y., Philipps, D., Pillon, V., Pintsuk, M., Piovesan, G., Pires Dos Reis, Piron, Lidia, Pironti, A., Pisano, F., Pitts, R., Pizzo, F., Plyusnin, V., Pomaro, N., Pompilian, O. G., Pool, P. J., Popovichev, S., Porfiri, M. T., Porosnicu, C., Porton, M., Possnert, G., Potzel, S., Powell, T., Pozzi, J., Prajapati, V., Prakash, R., Prestopino, G., Price, D., Price, M., Price, R., Prior, P., Proudfoot, R., Pucella, G., Puglia, P., Puiatti, M. E., Pulley, D., Purahoo, K., Pã¼tterich, T. h., Rachlew, E., Rack, M., Ragona, R., Rainford, M. S. J., Rakha, A., Ramogida, G., Ranjan, S., Rapson, C. J., Rasmussen, J. J., Rathod, K., Rattã¡, G., Ratynskaia, S., Ravera, G., Rayner, C., Rebai, M., Reece, D., Reed, A., Rã©fy, D., Regan, B., Regaã±a, J., Reich, M., Reid, N., Reimold, F., Reinhart, M., Reinke, M., Reiser, D., Rendell, D., Reux, C., Reyes, Cortes, Reynolds, S. D. A., Riccardo, S., Richardson, V., Riddle, N., Rigamonti, K., Rimini, D., Risner, F. G., Riva, J., Roach, M., Robins, C., Robinson, R. J., Robinson, S. A., Robson, T., Roccella, D. W., Rodionov, R., Rodrigues, R., Rodriguez, P., Rohde, J., Romanelli, V., Romanelli, F., Romanelli, M., Romazanov, S., Rowe, J., Rubel, S., Rubinacci, M., Rubino, G., Ruchko, G., Ruiz, L., Ruset, M., Rzadkiewicz, C., Saarelma, J., Sabot, S., Safi, R., Sagar, E., Saibene, P., Saint, Laurent, Salewski, F., Salmi, M., Salmon, A., Salzedas, R., Samaddar, F., Samm, D., Sandiford, U., Santa, D., Santala, P., Santos, M. I. K., Santucci, B., Sartori, A., Sartori, F., Sauter, R., Scannell, O., Schlummer, R., Schmid, T., Schmidt, K., Schmuck, V., Schneider, S., Schã¶pf, M., Schwã¶rer, K., Scott, D., Sergienko, S. D., Sertoli, G., Shabbir, M., Sharapov, A., Shaw, S. E., Shaw, A., Sheikh, R., Shepherd, H., Shevelev, A., Shumack, A., Sias, A., Sibbald, G., Sieglin, M., Silburn, B., Silva, S., Silva, A., Simmons, C., Simpson, P. A., Simpson, Hutchinson, Sinha, J., Sipilã¤, A., Sips, S. K., Sirã©n, A. C. C., Sirinelli, P., Sjã¶strand, A., Skiba, H., Skilton, M., Slabkowska, R., Slade, K., Smith, B., Smith, N., Smith, P. G., Smith, R., Smithies, T. J., Snoj, M., Soare, L., Solano, S., Somers, E. R., Sommariva, A., Sonato, C., Piergiorgio, Sopplesa, Sousa, A., Sozzi, J., Spagnolo, C., Silvia, Spelzini, Spineanu, T., Stables, F., Stamatelatos, G., Stamp, I., Staniec, M. F., Stankå«nas, P., Stan, Sion, Stead, C., Stefanikova, M. J., Stepanov, E., Stephen, I., Stephen, A. V., Stevens, M., Stevens, A., Strachan, B. D., Strand, J., Strauss, P., Strã¶m, H. R., Stubbs, P., Studholme, G., Subba, W., Summers, F., Svensson, H. P., Åšwiderski, J., Szabolics, Å. ., Szawlowski, T., Szepesi, M., Suzuki, G., Tã¡l, T. T., Tala, B., Talbot, T., Talebzadeh, A. R., Taliercio, S., Cesare, Tamain, Tame, P., Tang, C., Tardocchi, W., Taroni, M., Taylor, L., Taylor, D., Tegnered, K. A., Telesca, D., Teplova, G., Terranova, N., David, Testa, Tholerus, D., Thomas, E., Thomas, J., Thomas, J. D., Thompson, P., Thompson, A., Thompson, C. A., Thorne, V. K., Thornton, L., Thrysã¸e, A., Tigwell, A. S., Tipton, P. A., Tiseanu, N., Tojo, I., Tokitani, H., Tolias, M., Tomeå¡, P., Tonner, M., Towndrow, P., Trimble, M., Tripsky, P., Tsalas, M., Tsavalas, M., Tskhakaya, Jun, Turner, D., Turner, I., Turnyanskiy, M. M., Tvalashvili, M., Tyrrell, G., Uccello, S. G. J., Abidin, Ul, Uljanovs, Z., Ulyatt, J., Urano, D., Uytdenhouwen, H., Vadgama, I., Valcarcel, A. P., Valentinuzzi, D., Valisa, M., Vallejos, Olivares, Valovic, P., Van De Mortel, Van, Eester, Van, Renterghem, Van, Rooij, Varje, G. J., Varoutis, J., Vartanian, S., Vasava, S., Vasilopoulou, K., Vega, T., Verdoolaege, J., Verhoeven, G., Verona, R., Verona, Rinati, Veshchev, G., Vianello, E., Vicente, N., Viezzer, J., Villari, E., Villone, S., Vincenzi, F., Pietro, Vinyar, Viola, I., Vitins, B., Vizvary, A., Vlad, Z., Voitsekhovitch, M., Vondrã¡äek, I., Vora, P., Vu, N., Pires De Sa, Wakeling, W. W., Waldon, B., Walkden, C. W. F., Walker, N., Walker, M., Walsh, R., Wang, M., Wang, E., Warder, N., Warren, S., Waterhouse, R. J., Watkins, J., Watts, N. W., Wauters, C., Weckmann, T., Weiland, A., Weisen, J., Weiszflog, H., Wellstood, M., West, C., Wheatley, A. T., Whetham, M. R., Whitehead, S., Whitehead, A. M., Widdowson, B. D., Wiesen, A. M., Wilkinson, S., Williams, J., Wilson, M., Wilson, A. R., Wilson, D. J., Wilson, H. R., Wischmeier, J., Withenshaw, M., Withycombe, G., Witts, A., Wood, D. M., Wood, D., Woodley, R., Wray, C., Wright, S., Wright, J., J. C., Wu, Wukitch, J., Wynn, S., Xu, A., Yadikin, T., Yanling, D., Yao, W., Yavorskij, L., Yoo, V., Young, M. G., Young, C., Young, D., Young, I. D., Zacks, R., Zagorski, J., Zaitsev, R., Zanino, F. S., Zarins, R., Zastrow, A., Zerbini, K. D., Zhang, M., Zhou, W., Zilli, Y., Zoita, E., Zoletnik, V., Zychor, S., I, Universidad de Sevilla. Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla. RNM138: Física Nuclear Aplicada, JET Contributors, Viola, B., Department of Physics, and Materials Physics
- Subjects
Nuclear and High Energy Physics ,Electron density ,Materials science ,Physics::Instrumentation and Detectors ,Thomson scattering ,education ,114 Physical sciences ,01 natural sciences ,010305 fluids & plasmas ,Pedestal ,ASDEX Upgrade ,Physics::Plasma Physics ,Position (vector) ,0103 physical sciences ,Pedestal position ,pedestal stability ,010306 general physics ,Jet (fluid) ,EUROPED ,JET ,pedestal ,pedestal position ,Pedestal stability ,Plasma ,Condensed Matter Physics ,Electron temperature ,Atomic physics ,physics - Abstract
The electron temperature and density pedestals tend to vary in their relative radial positions, as observed in DIII-D (Beurskens et al 2011 Phys. Plasmas 18 056120) and ASDEX Upgrade (Dunne et al 2017 Plasma Phys. Control. Fusion 59 14017). This so-called relative shift has an impact on the pedestal magnetohydrodynamic (MHD) stability and hence on the pedestal height (Osborne et al 2015 Nucl. Fusion 55 063018). The present work studies the effect of the relative shift on pedestal stability of JET ITER-like wall (JET-ILW) baseline low triangularity (δ) unseeded plasmas, and similar JET-C discharges. As shown in this paper, the increase of the pedestal relative shift is correlated with the reduction of the normalized pressure gradient, therefore playing a strong role in pedestal stability. Furthermore, JET-ILW tends to have a larger relative shift compared to JET carbon wall (JET-C), suggesting a possible role of the plasma facing materials in affecting the density profile location. Experimental results are then compared with stability analysis performed in terms of the peeling-ballooning model and with pedestal predictive model EUROPED (Saarelma et al 2017 Plasma Phys. Control. Fusion). Stability analysis is consistent with the experimental findings, showing an improvement of the pedestal stability, when the relative shift is reduced. This has been ascribed mainly to the increase of the edge bootstrap current, and to minor effects related to the increase of the pedestal pressure gradient and narrowing of the pedestal pressure width. Pedestal predictive model EUROPED shows a qualitative agreement with experiment, especially for low values of the relative shift. EURATOM 633053 Swedish Energy Agency 40146-1
- Published
- 2018
6. Isotope effects on L-H threshold and confinement in tokamak plasmas
- Author
-
Maggi, C. F., Weisen, H., Hillesheim, J. C., Chankin, A., Delabie, E., Horvath, L., Auriemma, F., Carvalho, I. S., Corrigan, G., Flanagan, J., Garzotti, L., Keeling, D., King, D., Lerche, E., Lorenzini, R., Maslov, M., Menmuir, S., Saarelma, S., Sips, A. C. C., Solano, E. R., Belonohy, E., Casson, F. J., Challis, C., Giroud, C., Parail, V., Silva, C., Valisa, M., Lambertz, N., Lane, H. T., Lang, C., Lanthaler, P. T., Lapins, S., Lasa, J., Last, A., Åaszyå„ska, J. R., Lawless, E., Lawson, R., Lawson, A., Lazaros, K. D., Lazzaro, A., Leddy, E., Lee, J., Lefebvre, S., Leggate, X., Lehmann, H. J., Lehnen, J., Leichtle, M., Leichuer, D., Leipold, P., Lengar, F., Lennholm, I., Lerche, M., Lescinskis, E., Lesnoj, A., Letellier, S., Leyland, E., Leysen, M., Li, W., Liang, L., Likonen, Y., Linke, J., Linsmeier, J., Lipschultz, C. h., Liu, B., Liu, G., Schiavo, Lo, Loarer, V. P., Loarte, T., Lobel, A., Lomanowski, R. C., Lomas, B., Lã¶nnroth, P. J., Lã³pez, J., J. M., Lã³pez, Razola, Lorenzini, J., Losada, R., Lovell, U., Loving, J. J., Lowry, A. B., Luce, C., Lucock, T., Lukin, R. M. A., Luna, A., Lungaroni, C., Lungu, M., Lungu, C. P., Lunniss, M., Lupelli, A., Lyssoivan, I., Macdonald, A., Macheta, N., Maczewa, P., Magesh, K., Maget, B., Maggi, P., Maier, C., Mailloux, H., Makkonen, J., Makwana, T., Malaquias, R., Malizia, A., Manas, A., Manning, P., Manso, A., Mantica, M. E., Mantsinen, P., Manzanares, M., Maquet, A., Marandet, P. h., Marcenko, Y., Marchetto, N., Marchuk, C., Marinelli, O., Marinucci, M., Markoviä, M., Marocco, T., Marot, D., Marren, L., Marshal, C. A., Martin, R., Martin, A., Martìn De Aguilera, Martã¬nez, A., F. J., Martã¬n, Solã¬s, Martynova, J. R., Maruyama, Y., Masiello, S., Maslov, A., Matejcik, M., Mattei, S., Matthews, M., Maviglia, G. F., Mayer, F., Mayoral, M., M. L., May, Smith, Mazon, T., Mazzotta, D., Mcadams, C., Mccarthy, R., Mcclements, P. J., Mccormack, K. G., Mccullen, O., Mcdonald, P. A., Mcintosh, D., Mckean, S., Mckehon, R., Meadows, J., Meakins, R. C., Medina, A., Medland, F., Medley, M., Meigh, S., Meigs, S., Meisl, A. G., Meitner, G., Meneses, S., Menmuir, L., Mergia, S., Merrigan, K., Mertens, I. R., Meshchaninov, P. h., Messiaen, S., Meyer, A., Mianowski, H., Michling, S., Middleton, Gear, Miettunen, D., Militello, J., Militello, Asp, Miloshevsky, E., Mink, G., Minucci, F., Miyoshi, S., Mlynã¡å™, Y., Molina, J., Monakhov, D., Moneti, I., Mooney, M., Moradi, R., Mordijck, S., Moreira, S., Moreno, L., Moro, R., Morris, F., Morris, A. W., Moser, J., Mosher, L., Moulton, S., Murari, D., Muraro, A., Murphy, A., Asakura, S., N. N., Na, Nabais, Y. S., Naish, F., Nakano, R., Nardon, T., Naulin, E., Nave, V., Nedzelski, M. F. F., Nemtsev, I., Nespoli, G., Neto, F., Neu, A., Neverov, R., Newman, V. S., Nicholls, M., Nicolas, K. J., Nielsen, T., Nielsen, A. H., Nilsson, P., Nishijima, E., Noble, D., Nocente, C., Nodwell, M., Nordlund, D., Nordman, K., Nouailletas, H., Nunes, R., Oberkofler, I., Odupitan, M., Ogawa, T., O'Gorman, M. T., Okabayashi, T., Olney, M., Omolayo, R., O'Mullane, O., Ongena, M., Orsitto, J., Orszagh, F., Oswuigwe, J., Otin, B. I., Owen, R., Paccagnella, A., Pace, R., Pacella, N., Packer, D., Page, L. W., Pajuste, A., Palazzo, E., Pamela, S., Panja, S., Papp, S., Paprok, P., Parail, R., Park, V., Parra, Diaz, Parsons, F., Pasqualotto, M., Patel, R., Pathak, A., Paton, S., Patten, D., Pau, H., Pawelec, A., Paz, Soldan, Peackoc, C., Pearson, A., Pehkonen, I. J., Peluso, S. P., Penot, E., Pereira, C., Pereira, A., Pereira, Puglia, P. P., Perez Von Thun, Peruzzo, C., Peschanyi, S., Peterka, S., Petersson, M., Petravich, P., Petre, G., Petrella, A., Petråilka, N., Peysson, V., Pfefferlã©, Y., Philipps, D., Pillon, V., Pintsuk, M., Piovesan, G., Pires Dos Reis, Piron, Lidia, Pironti, A., Pisano, F., Pitts, R., Pizzo, F., Plyusnin, V., Pomaro, N., Pompilian, O. G., Pool, P. J., Popovichev, S., Porfiri, M. T., Porosnicu, C., Porton, M., Possnert, G., Potzel, S., Powell, T., Pozzi, J., Prajapati, V., Prakash, R., Prestopino, G., Price, D., Price, M., Price, R., Prior, P., Proudfoot, R., Pucella, G., Puglia, P., Puiatti, M. E., Pulley, D., Purahoo, K., Pã¼tterich, T. h., Rachlew, E., Rack, M., Ragona, R., Rainford, M. S. J., Rakha, A., Ramogida, G., Ranjan, S., Rapson, C. J., Rasmussen, J. J., Rathod, K., Rattã¡, G., Ratynskaia, S., Ravera, G., Rayner, C., Rebai, M., Reece, D., Reed, A., Rã©fy, D., Regan, B., Regaã±a, J., Reich, M., Reid, N., Reimold, F., Reinhart, M., Reinke, M., Reiser, D., Rendell, D., Reux, C., Reyes, Cortes, Reynolds, S. D. A., Riccardo, S., Richardson, V., Riddle, N., Rigamonti, K., Rimini, D., Risner, F. G., Riva, J., Roach, M., Robins, C., Robinson, R. J., Robinson, S. A., Robson, T., Roccella, D. W., Rodionov, R., Rodrigues, R., Rodriguez, P., Rohde, J., Romanelli, V., Romanelli, F., Romanelli, M., Romazanov, S., Rowe, J., Rubel, S., Rubinacci, M., Rubino, G., Ruchko, G., Ruiz, L., Ruset, M., Rzadkiewicz, C., Saarelma, J., Sabot, S., Safi, R., Sagar, E., Saibene, P., Saint, Laurent, Salewski, F., Salmi, M., Salmon, A., Salzedas, R., Samaddar, F., Samm, D., Sandiford, U., Santa, D., Santala, P., Santos, M. I. K., Santucci, B., Sartori, A., Sartori, F., Sauter, R., Scannell, O., Schlummer, R., Schmid, T., Schmidt, K., Schmuck, V., Schneider, S., Schã¶pf, M., Schwã¶rer, K., Scott, D., Sergienko, S. D., Sertoli, G., Shabbir, M., Sharapov, A., Shaw, S. E., Shaw, A., Sheikh, R., Shepherd, H., Shevelev, A., Shumack, A., Sias, A., Sibbald, G., Sieglin, M., Silburn, B., Silva, S., Silva, A., Simmons, C., Simpson, P. A., Simpson, Hutchinson, Sinha, J., Sipilã¤, A., Sips, S. K., Sirã©n, A. C. C., Sirinelli, P., Sjã¶strand, A., Skiba, H., Skilton, M., Slabkowska, R., Slade, K., Smith, B., Smith, N., Smith, P. G., Smith, R., Smithies, T. J., Snoj, M., Soare, L., Solano, S., Somers, E. R., Sommariva, A., Sonato, C., Piergiorgio, Sopplesa, Sousa, A., Sozzi, J., Spagnolo, C., Silvia, Spelzini, Spineanu, T., Stables, F., Stamatelatos, G., Stamp, I., Staniec, M. F., Stankå«nas, P., Stan, Sion, Stead, C., Stefanikova, M. J., Stepanov, E., Stephen, I., Stephen, A. V., Stevens, M., Stevens, A., Strachan, B. D., Strand, J., Strauss, P., Strã¶m, H. R., Stubbs, P., Studholme, G., Subba, W., Summers, F., Svensson, H. P., Åšwiderski, J., Szabolics, Å. ., Szawlowski, T., Szepesi, M., Suzuki, G., Tã¡l, T. T., Tala, B., Talbot, T., Talebzadeh, A. R., Taliercio, S., Cesare, Tamain, Tame, P., Tang, C., Tardocchi, W., Taroni, M., Taylor, L., Taylor, D., Tegnered, K. A., Telesca, D., Teplova, G., Terranova, N., David, Testa, Tholerus, D., Thomas, E., Thomas, J., Thomas, J. D., Thompson, P., Thompson, A., Thompson, C. A., Thorne, V. K., Thornton, L., Thrysã¸e, A., Tigwell, A. S., Tipton, P. A., Tiseanu, N., Tojo, I., Tokitani, H., Tolias, M., Tomeå¡, P., Tonner, M., Towndrow, P., Trimble, M., Tripsky, P., Tsalas, M., Tsavalas, M., Tskhakaya, Jun, Turner, D., Turner, I., Turnyanskiy, M. M., Tvalashvili, M., Tyrrell, G., Uccello, S. G. J., Abidin, Ul, Uljanovs, Z., Ulyatt, J., Urano, D., Uytdenhouwen, H., Vadgama, I., Valcarcel, A. P., Valentinuzzi, D., Vallejos, Olivares, Valovic, P., Van De Mortel, Van, Eester, Van, Renterghem, Van, Rooij, Varje, G. J., Varoutis, J., Vartanian, S., Vasava, S., Vasilopoulou, K., Vega, T., Verdoolaege, J., Verhoeven, G., Verona, R., Verona, Rinati, Veshchev, G., Vianello, E., Vicente, N., Viezzer, J., Villari, E., Villone, S., Vincenzi, F., Pietro, Vinyar, Viola, I., Vitins, B., Vizvary, A., Vlad, Z., Voitsekhovitch, M., Vondrã¡äek, I., Vora, P., Vu, N., Pires De Sa, Wakeling, W. W., Waldon, B., Walkden, C. W. F., Walker, N., Walker, M., Walsh, R., Wang, M., Wang, E., Warder, N., Warren, S., Waterhouse, R. J., Watkins, J., Watts, N. W., Wauters, C., Weckmann, T., Weiland, A., Weisen, J., Weiszflog, H., Wellstood, M., West, C., Wheatley, A. T., Whetham, M. R., Whitehead, S., Whitehead, A. M., Widdowson, B. D., Wiesen, A. M., Wilkinson, S., Williams, J., Wilson, M., Wilson, A. R., Wilson, D. J., Wilson, H. R., Wischmeier, J., Withenshaw, M., Withycombe, G., Witts, A., Wood, D. M., Wood, D., Woodley, R., Wray, C., Wright, S., Wright, J., J. C., Wu, Wukitch, J., Wynn, S., Xu, A., Yadikin, T., Yanling, D., Yao, W., Yavorskij, L., Yoo, V., Young, M. G., Young, C., Young, D., Young, I. D., Zacks, R., Zagorski, J., Zaitsev, R., Zanino, F. S., Zarins, R., Zastrow, A., Zerbini, K. D., Zhang, M., Zhou, W., Zilli, Y., Zoita, E., Zoletnik, V., Zychor, S., and JET Contributors
- Subjects
Tokamak ,Materials science ,Isotope ,Turbulence ,Magnetic confinement fusion ,L-H threshold ,Plasma ,Condensed Matter Physics ,01 natural sciences ,confinement ,isotope effects ,tokamaks ,010305 fluids & plasmas ,law.invention ,Ion ,Nuclear Energy and Engineering ,Physics::Plasma Physics ,law ,Physics::Space Physics ,0103 physical sciences ,Kinetic isotope effect ,Physics::Atomic Physics ,Atomic physics ,010306 general physics - Abstract
The dependence of plasma transport and confinement on the main hydrogenic ion isotope mass is of fundamental importance for understanding turbulent transport and, therefore, for accurate extrapolations of confinement from present tokamak experiments, which typically use a single hydrogen isotope, to burning plasmas such as ITER, which will operate in deuterium-tritium mixtures. Knowledge of the dependence of plasma properties and edge transport barrier formation on main ion species is critical in view of the initial, low-activation phase of ITER operations in hydrogen or helium and of its implications on the subsequent operation in deuterium-tritium. The favourable scaling of global energy confinement time with isotope mass, which has been observed in many tokamak experiments, remains largely unexplained theoretically. Moreover, the mass scaling observed in experiments varies depending on the plasma edge conditions. In preparation for upcoming deuterium-tritium experiments in the JET tokamak with the ITER-like Be/W Wall (JET-ILW), a thorough experimental investigation of isotope effects in hydrogen, deuterium and tritium plasmas is being carried out, in order to provide stringent tests of plasma energy, particle and momentum transport models. Recent hydrogen and deuterium isotope experiments in JET-ILW on L-H power threshold, L-mode and H-mode confinement are reviewed and discussed in the context of past and more recent isotope experiments in tokamak plasmas, highlighting common elements as well as contrasting observations that have been reported. The experimental findings are discussed in the context of fundamental aspects of plasma transport models.
- Published
- 2018
- Full Text
- View/download PDF
7. Erosion and deposition in the JET divertor during the second ITER-like wall campaign
- Author
-
Mayer, M., Krat, S., Baron-Wiechec, A., Gasparyan, Y., Heinola, K., Koivuranta, S., Likonen, J., Ruset, C., De Saint-Aubin, G., Litaudon, Widdowson A., Abduallev, X., Abhangi, S., Abreu, M., Afzal, P., Aggarwal, M., Ahlgren, K. M., Ahn, T., J. H., Aho, Mantila, Aiba, L., Airila, N., Albanese, M., Aldred, R., Alegre, V., Alessi, D., Aleynikov, E., Alfier, P., Alberto, Alkseev, Allinson, A., Alper, M., Alves, B., Ambrosino, E., Ambrosino, G., Amicucci, R., Amosov, L., Andersson, Sundã©n, Angelone, E., Anghel, M., Angioni, M., Appel, C., Appelbee, L., Arena, C., Ariola, P., Arnichand, M., Arshad, H., Ash, S., Ashikawa, A., Aslanyan, N., Asunta, V., Auriemma, O., Fulvio, Austin, Avotina, Y., Axton, L., Ayres, M. D., Bacharis, C., Baciero, M., Baiã¡o, A., Bailey, D., Baker, S., Balboa, A., Balden, I., Balshaw, M., Bament, N., Banks, R., Baranov, J. W., Barnard, Y. F., Barnes, M. A., Barnes, D., Barnsley, M., Baron, Wiechec, Barrera, Orte, Baruzzo, L., Matteo, Basiuk, Bassan, V., Bastow, M., Batista, R., Batistoni, A., Baughan, P., Bauvir, R., Baylor, B., Bazylev, L., Beal, B., Beaumont, J., Beckers, P. S., Beckett, M., Becoulet, B., Bekris, A., Beldishevski, N., Bell, M., Belli, K., Bellinger, F., Belonohy, M., Ben, Ayed, Benterman, N., Bergsã¥ker, N. A., Bernardo, H., Bernert, J., Berry, M., Bertalot, M., Besliu, L., Beurskens, C., Bieg, M., Bielecki, B., Biewer, J., Bigi, T., Bã¬lkovã¡, M., Binda, P., Bisoffi, F., Bizarro, A., Bjã¶rkas, J. P. S., Blackburn, C., Blackman, J., Blackman, K., Blanchard, T. R., Blatchford, P., Bobkov, P., Boboc, V., Bodnã¡r, A., Bogar, G., Bolshakova, O., Bolzonella, I., Tommaso, Bonanomi, Bonelli, N., Boom, F., Booth, J., Borba, J., Borodin, D., Borodkina, D., Botrugno, I., Bottereau, A., Boulting, C., Bourdelle, P., Bowden, C., Bower, M., Bowman, C., Boyce, C., Boyd, T., Boyer, C., Bradshaw, H. J., Braic, J. M. A., Bravanec, V., Breizman, R., Bremond, B., Brennan, S., Breton, P. D., Brett, S., Brezinsek, A., Bright, S., Brix, M. D. J., Broeckx, M., Brombin, W., Matteo, Broså‚awski, Brown, A., Brown, D. P. D., Bruno, M., Bucalossi, E., Buch, J., Buchanan, J., Buckley, J., Budny, M. A., Bufferand, R., Bulman, H., Bulmer, M., Bunting, N., Buratti, P., Burckhart, P., Buscarino, A., Busse, A., Butler, A., Bykov, N. K., Byrne, I., Cahyna, J., Calabrã², P., Calvo, G., Camenen, I., Camp, Y., Campling, P., Cane, D. C., Cannas, J., Capel, B., Card, A. J., Cardinali, P. J., Carman, A., Carr, P., Carralero, M., Carraro, D., Carvalho, L., Carvalho, B. B., Carvalho, I., Casson, P., Castaldo, F. J., Catarino, C., Caumont, N., Causa, J., Cavazzana, F., Cave, Ayland, Cavinato, K., Cecconello, M., Ceccuzzi, M., Cecil, S., Cenedese, E., Angelo, Cesario, Challis, R., Chandler, C. D., Chandra, M., Chang, D., Chankin, C. S., Chapman, A., Chapman, I. T., Chernyshova, S. C., Chitarin, M., Giuseppe, Ciraolo, Ciric, G., Citrin, D., Clairet, J., Clark, F., Clark, E., Clarkson, M., Clatworthy, R., Clements, D., Cleverly, C., Coad, M., Coates, J. P., Cobalt, P. A., Coccorese, A., Cocilovo, V., Coda, V., Coelho, S., Coenen, R., Coffey, J. W., Colas, I., Collins, L., Conka, S., Conroy, D., Conway, S., Coombs, N., Cooper, D., Corradino, S. R., Corre, C., Corrigan, Y., Cortes, G., Coster, S., Couchman, D., Cox, A. S., Craciunescu, M. P., Cramp, T., Craven, S., Crisanti, R., Croci, F., Croft, G., Crombã©, D., Crowe, K., Cruz, R., Cseh, N., Cufar, G., Cullen, A., Curuia, A., Czarnecka, M., Dabirikhah, A., Dalgliesh, H., Dalley, P., Dankowski, S., Darrow, J., Davies, D., Davis, O., Day, W., Day, C., I. E., Bock, De, Castro, De, De La Cal, De La Luna, Masi, De, Pablos, De, J. L., Temmerman, De, Tommasi, De, Vries, De, Deakin, P., Deane, K., Degli, Agostini, Dejarnac, F., Delabie, R., Den, Harder, Dendy, N., Denis, R. O., Denner, J., Devaux, P., Devynck, S., Maio, Di, Siena, Di, Troia, Di, Dinca, C., D'Inca, P., Ding, R., Dittmar, B., Doerk, T., Doerner, H., Donnã©, R. P., Dorling, T., S. E., Dormido, Canto, Doswon, S., Douai, S., Doyle, D., Drenik, P. T., Drewelow, A., Drews, P., Duckworth, P., Dumont, P. h., Dumortier, R., Dunai, P., Dunne, D., Äžuran, M., Durodiã©, I., Dutta, F., Duval, P., Dux, B. P., Dylst, R., Dzysiuk, K., Edappala, N., Edmond, P. V., Edwards, J., Edwards, A. M., Eich, J., Ekedahl, T. h., Jorf, El, Elsmore, R., Enachescu, C. G., Ericsson, M., Eriksson, G., Eriksson, F., Eriksson, J., Esposito, L. G., Esquembri, B., Esser, S., Esteve, H. G., Evans, D., Evans, B., Evison, G. E., Ewart, G., Fagan, G. D., Faitsch, D., Falie, M., Fanni, D., Fasoli, A., Faustin, A., Fawlk, J. M., Fazendeiro, N., Fedorczak, L., Felton, N., Fenton, R. C., Fernades, K., Fernandes, A., Ferreira, H., Fessey, J., Fã©vrier, J. A., Ficker, O., Field, O., Fietz, A., Figueiredo, S., Figueiredo, A., Fil, J., Finburg, A., Firdaouss, P., Fischer, M., Fittill, U., Fitzgerald, L., Flammini, M., Flanagan, D., Fleming, J., Flinders, C., Fonnesu, K., Fontdecaba, N., Formisano, J. M., Forsythe, A., Fortuna, L., Fortuna, Zalesna, Fortune, E., Foster, M., Franke, S., Franklin, T., Frasca, T., Frassinetti, M., Freisinger, L., Fresa, M., Frigione, R., Fuchs, D., Fuller, V., Futatani, D., Fyvie, S., Gã¡l, J., Galassi, K., Gaå‚azka, D., Galdon, Quiroga, Gallagher, J., Gallart, J., Galvã¡o, D., Gao, R., Gao, X., Garcia, Y., Garcia, Carrasco, Garcã¬a, Muã±oz, Gardarein, M., Garzotti, J. L., Gaudio, L., Gauthier, P., Gear, E., Gee, D. F., Geiger, S. J., Gelfusa, B., Gerasimov, M., Gervasini, S., Gethins, G., Ghani, M., Ghate, Z., Gherendi, M., Giacalone, M., Giacomelli, J. C., Gibson, L., Giegerich, C. S., Gil, T., Gil, C., Gilligan, L., Gin, S., Giovannozzi, D., Girardo, E., Giroud, J. B., Giruzzi, C., Gerardo, Glã¶ggler, Godwin, S., Goff, J., Gohil, J., Goloborod'Ko, P., Gomes, V., Goncalves, R., Goniche, B., Goodliffe, M., Goodyear, M., Gorini, A., Gosk, G., Goulding, M., Goussarov, R., Gowland, A., Graham, R., Graham, B., Graves, M. E., Grazier, J. P., Grazier, N., Green, P., Greuner, N. R., Grierson, H., Griph, B., Grisolia, F. S., Grist, C., Groth, D., Grove, M., Grundy, R., Grzonka, C. N., Guard, J., Guã©rard, D., Guillemaut, C., Guirlet, C., Gurl, R., Utoh, C., Hackett, H. H., Hacquin, L. J., Hagar, S., Hager, A., Hakola, R., Halitovs, A., Hall, M., S. J., Hallworth, Cook, S. P., Hamlyn, Harris, Hammond, C., Harrington, K., Harrison, C., Harting, J., Hasenbeck, D., Hatano, F., Hatch, Y., Haupt, D. R., Hawes, T. D. V., Hawkes, J., Hawkins, N. C., Hawkins, J., Haydon, P., Hayter, P. W., Hazel, N., Heesterman, S., Heinola, P. J. L., Hellesen, K., Hellsten, C., Helou, T., Hemming, W., Hender, O. N., Henderson, T. C., Henderson, M., Henriques, S. S., Hepple, R., Hermon, D., Hertout, G., Hidalgo, P., Highcock, C., Hill, E. G., Hillairet, M., Hillesheim, J., Hillis, J., Hizanidis, D., Hjalmarsson, K., Hobirk, A., Hodille, J., Hogben, E., Hogeweij, C. H. A., Hollingsworth, G. M. D., Hollis, A., Homfray, S., Horã¡äek, D. A., Hornung, J., Horton, G., Horton, A. R., Horvath, L. D., Hotchin, L., Hough, S. P., Howarth, M. R., Hubbard, P. J., Huber, A., Huddleston, V., Hughes, T. M., Huijsmans, M., Hunter, G. T. A., Huynh, C. L., Hynes, P., Iglesias, A. M., Imazawa, D., Imbeaux, N., Imrã¬å¡ek, F., Incelli, M., Innocente, M., Irishkin, P., Ivanova, Stanik, Jachmich, I., Jacobsen, S., Jacquet, A. S., Jansons, P., Jardin, J., Jã¤rvinen, A., Jaulmes, A., Jednorã³g, F., Jenkins, S., Jeong, I., Jepu, C., Joffrin, I., Johnson, E., Johnson, R., Johnston, T., Jane, Joita, Jones, L., Jones, G., Hoshino, T. T. C., Kallenbach, K. K., Kamiya, A., Kaniewski, K., Kantor, J., Kappatou, A., Karhunen, A., Karkinsky, J., Karnowska, D., Kaufman, I., Kaveney, M., Kazakov, G., Kazantzidis, Y., Keeling, V., Keenan, D. L., Keep, T., Kempenaars, J., Kennedy, M., Kenny, C., Kent, D., Kent, J., Khilkevich, O. N., Kim, E., Kim, H. T., Kinch, H. S., King, A., King, C., King, D., Kinna, R. F., Kiptily, D. J., Kirk, V., Kirov, A., Kirschner, K., Kizane, A., Klepper, G., Klix, C., Knight, A., Knipe, P., Knott, S. J., Kobuchi, S., Kã¶chl, T., Kocsis, F., Kodeli, G., Kogan, I., Kogut, L., Koivuranta, D., Kominis, S., Kã¶ppen, Y., Kos, M., Koskela, B., Koslowski, T., Koubiti, H. R., Kovari, M., Kowalska, Strzè©ciwilk, Krasilnikov, E., Krasilnikov, A., Krawczyk, V., Kresina, N., Krieger, M., Krivska, K., Kruezi, A., Ksiaå¼ek, U., Kukushkin, I., Kundu, A., Kurki, Suonio, Kwak, T., Kwiatkowski, S., Kwon, R., Laguardia, O. J., Lahtinen, L., Laing, A., Lam, A., Lambertz, N., Lane, H. T., Lang, C., Lanthaler, P. T., Lapins, S., Lasa, J., Last, A., Åaszyå„ska, J. R., Lawless, E., Lawson, R., Lawson, A., Lazaros, K. D., Lazzaro, A., Leddy, E., Lee, J., Lefebvre, S., Leggate, X., Lehmann, H. J., Lehnen, J., Leichtle, M., Leichuer, D., Leipold, P., Lengar, F., Lennholm, I., Lerche, M., Lescinskis, E., Lesnoj, A., Letellier, S., Leyland, E., Leysen, M., Li, W., Liang, L., Likonen, Y., Linke, J., Linsmeier, J., Lipschultz, C. h., Liu, B., Liu, G., Schiavo, Lo, Loarer, V. P., Loarte, T., Lobel, A., Lomanowski, R. C., Lomas, B., Lã¶nnroth, P. J., Lã³pez, J., J. M., Lã³pez, Razola, Lorenzini, J., Losada, R., Lovell, U., Loving, J. J., Lowry, A. B., Luce, C., Lucock, T., Lukin, R. M. A., Luna, A., Lungaroni, C., Lungu, M., Lungu, C. P., Lunniss, M., Lupelli, A., Lyssoivan, I., Macdonald, A., Macheta, N., Maczewa, P., Magesh, K., Maget, B., Maggi, P., Maier, C., Mailloux, H., Makkonen, J., Makwana, T., Malaquias, R., Malizia, A., Manas, A., Manning, P., Manso, A., Mantica, M. E., Mantsinen, P., Manzanares, M., Maquet, A., Marandet, P. h., Marcenko, Y., Marchetto, N., Marchuk, C., Marinelli, O., Marinucci, M., Markoviä, M., Marocco, T., Marot, D., Marren, L., Marshal, C. A., Martin, R., Martin, A., Martìn De Aguilera, Martã¬nez, A., F. J., Martã¬n, Solã¬s, Martynova, J. R., Maruyama, Y., Masiello, S., Maslov, A., Matejcik, M., Mattei, S., Matthews, M., Maviglia, G. F., Mayer, F., Mayoral, M., M. L., May, Smith, Mazon, T., Mazzotta, D., Mcadams, C., Mccarthy, R., Mcclements, P. J., Mccormack, K. G., Mccullen, O., Mcdonald, P. A., Mcintosh, D., Mckean, S., Mckehon, R., Meadows, J., Meakins, R. C., Medina, A., Medland, F., Medley, M., Meigh, S., Meigs, S., Meisl, A. G., Meitner, G., Meneses, S., Menmuir, L., Mergia, S., Merrigan, K., Mertens, I. R., Meshchaninov, P. h., Messiaen, S., Meyer, A., Mianowski, H., Michling, S., Middleton, Gear, Miettunen, D., Militello, J., Militello, Asp, Miloshevsky, E., Mink, G., Minucci, F., Miyoshi, S., Mlynã¡å™, Y., Molina, J., Monakhov, D., Moneti, I., Mooney, M., Moradi, R., Mordijck, S., Moreira, S., Moreno, L., Moro, R., Morris, F., Morris, A. W., Moser, J., Mosher, L., Moulton, S., Murari, D., Muraro, A., Murphy, A., Asakura, S., N. N., Na, Nabais, Y. S., Naish, F., Nakano, R., Nardon, T., Naulin, E., Nave, V., Nedzelski, M. F. F., Nemtsev, I., Nespoli, G., Neto, F., Neu, A., Neverov, R., Newman, V. S., Nicholls, M., Nicolas, K. J., Nielsen, T., Nielsen, A. H., Nilsson, P., Nishijima, E., Noble, D., Nocente, C., Nodwell, M., Nordlund, D., Nordman, K., Nouailletas, H., Nunes, R., Oberkofler, I., Odupitan, M., Ogawa, T., O'Gorman, M. T., Okabayashi, T., Olney, M., Omolayo, R., O'Mullane, O., Ongena, M., Orsitto, J., Orszagh, F., Oswuigwe, J., Otin, B. I., Owen, R., Paccagnella, A., Pace, R., Pacella, N., Packer, D., Page, L. W., Pajuste, A., Palazzo, E., Pamela, S., Panja, S., Papp, S., Paprok, P., Parail, R., Park, V., Parra, Diaz, Parsons, F., Pasqualotto, M., Patel, R., Pathak, A., Paton, S., Patten, D., Pau, H., Pawelec, A., Paz, Soldan, Peackoc, C., Pearson, A., Pehkonen, I. J., Peluso, S. P., Penot, E., Pereira, C., Pereira, A., Pereira, Puglia, P. P., Perez Von Thun, Peruzzo, C., Peschanyi, S., Peterka, S., Petersson, M., Petravich, P., Petre, G., Petrella, A., Petrå¾ilka, N., Peysson, V., Pfefferlã©, Y., Philipps, D., Pillon, V., Pintsuk, M., Piovesan, G., Pires Dos Reis, Piron, Lidia, Pironti, A., Pisano, F., Pitts, R., Pizzo, F., Plyusnin, V., Pomaro, N., Pompilian, O. G., Pool, P. J., Popovichev, S., Porfiri, M. T., Porosnicu, C., Porton, M., Possnert, G., Potzel, S., Powell, T., Pozzi, J., Prajapati, V., Prakash, R., Prestopino, G., Price, D., Price, M., Price, R., Prior, P., Proudfoot, R., Pucella, G., Puglia, P., Puiatti, M. E., Pulley, D., Purahoo, K., Pã¼tterich, T. h., Rachlew, E., Rack, M., Ragona, R., Rainford, M. S. J., Rakha, A., Ramogida, G., Ranjan, S., Rapson, C. J., Rasmussen, J. J., Rathod, K., Rattã¡, G., Ratynskaia, S., Ravera, G., Rayner, C., Rebai, M., Reece, D., Reed, A., Rã©fy, D., Regan, B., Regaã±a, J., Reich, M., Reid, N., Reimold, F., Reinhart, M., Reinke, M., Reiser, D., Rendell, D., Reux, C., Reyes, Cortes, Reynolds, S. D. A., Riccardo, S., Richardson, V., Riddle, N., Rigamonti, K., Rimini, D., Risner, F. G., Riva, J., Roach, M., Robins, C., Robinson, R. J., Robinson, S. A., Robson, T., Roccella, D. W., Rodionov, R., Rodrigues, R., Rodriguez, P., Rohde, J., Romanelli, V., Romanelli, F., Romanelli, M., Romazanov, S., Rowe, J., Rubel, S., Rubinacci, M., Rubino, G., Ruchko, G., Ruiz, L., Ruset, M., Rzadkiewicz, C., Saarelma, J., Sabot, S., Safi, R., Sagar, E., Saibene, P., Saint, Laurent, Salewski, F., Salmi, M., Salmon, A., Salzedas, R., Samaddar, F., Samm, D., Sandiford, U., Santa, D., Santala, P., Santos, M. I. K., Santucci, B., Sartori, A., Sartori, F., Sauter, R., Scannell, O., Schlummer, R., Schmid, T., Schmidt, K., Schmuck, V., Schneider, S., Schã¶pf, M., Schwã¶rer, K., Scott, D., Sergienko, S. D., Sertoli, G., Shabbir, M., Sharapov, A., Shaw, S. E., Shaw, A., Sheikh, R., Shepherd, H., Shevelev, A., Shumack, A., Sias, A., Sibbald, G., Sieglin, M., Silburn, B., Silva, S., Silva, A., Simmons, C., Simpson, P. A., Simpson, Hutchinson, Sinha, J., Sipilã¤, A., Sips, S. K., Sirã©n, A. C. C., Sirinelli, P., Sjã¶strand, A., Skiba, H., Skilton, M., Slabkowska, R., Slade, K., Smith, B., Smith, N., Smith, P. G., Smith, R., Smithies, T. J., Snoj, M., Soare, L., Solano, S., Somers, E. R., Sommariva, A., Sonato, C., Piergiorgio, Sopplesa, Sousa, A., Sozzi, J., Spagnolo, C., Silvia, Spelzini, Spineanu, T., Stables, F., Stamatelatos, G., Stamp, I., Staniec, M. F., Stankå«nas, P., Stan, Sion, Stead, C., Stefanikova, M. J., Stepanov, E., Stephen, I., Stephen, A. V., Stevens, M., Stevens, A., Strachan, B. D., Strand, J., Strauss, P., Strã¶m, H. R., Stubbs, P., Studholme, G., Subba, W., Summers, F., Svensson, H. P., Åšwiderski, J., Szabolics, Å. ., Szawlowski, T., Szepesi, M., Suzuki, G., Tã¡l, T. T., Tala, B., Talbot, T., Talebzadeh, A. R., Taliercio, S., Cesare, Tamain, Tame, P., Tang, C., Tardocchi, W., Taroni, M., Taylor, L., Taylor, D., Tegnered, K. A., Telesca, D., Teplova, G., Terranova, N., David, Testa, Tholerus, D., Thomas, E., Thomas, J., Thomas, J. D., Thompson, P., Thompson, A., Thompson, C. A., Thorne, V. K., Thornton, L., Thrysã¸e, A., Tigwell, A. S., Tipton, P. A., Tiseanu, N., Tojo, I., Tokitani, H., Tolias, M., Tomeå¡, P., Tonner, M., Towndrow, P., Trimble, M., Tripsky, P., Tsalas, M., Tsavalas, M., Tskhakaya, Jun, Turner, D., Turner, I., Turnyanskiy, M. M., Tvalashvili, M., Tyrrell, G., Uccello, S. G. J., Abidin, Ul, Uljanovs, Z., Ulyatt, J., Urano, D., Uytdenhouwen, H., Vadgama, I., Valcarcel, A. P., Valentinuzzi, D., Valisa, M., Vallejos, Olivares, Valovic, P., Van De Mortel, Van, Eester, Van, Renterghem, Van, Rooij, Varje, G. J., Varoutis, J., Vartanian, S., Vasava, S., Vasilopoulou, K., Vega, T., Verdoolaege, J., Verhoeven, G., Verona, R., Verona, Rinati, Veshchev, G., Vianello, E., Vicente, N., Viezzer, J., Villari, E., Villone, S., Vincenzi, F., Pietro, Vinyar, Viola, I., Vitins, B., Vizvary, A., Vlad, Z., Voitsekhovitch, M., Vondrã¡äek, I., Vora, P., Vu, N., Pires De Sa, Wakeling, W. W., Waldon, B., Walkden, C. W. F., Walker, N., Walker, M., Walsh, R., Wang, M., Wang, E., Warder, N., Warren, S., Waterhouse, R. J., Watkins, J., Watts, N. W., Wauters, C., Weckmann, T., Weiland, A., Weisen, J., Weiszflog, H., Wellstood, M., West, C., Wheatley, A. T., Whetham, M. R., Whitehead, S., Whitehead, A. M., Widdowson, B. D., Wiesen, A. M., Wilkinson, S., Williams, J., Wilson, M., Wilson, A. R., Wilson, D. J., Wilson, H. R., Wischmeier, J., Withenshaw, M., Withycombe, G., Witts, A., Wood, D. M., Wood, D., Woodley, R., Wray, C., Wright, S., Wright, J., J. C., Wu, Wukitch, J., Wynn, S., Xu, A., Yadikin, T., Yanling, D., Yao, W., Yavorskij, L., Yoo, V., Young, M. G., Young, C., Young, D., Young, I. D., Zacks, R., Zagorski, J., Zaitsev, R., Zanino, F. S., Zarins, R., Zastrow, A., Zerbini, K. D., Zhang, M., Zhou, W., Zilli, Y., Zoita, E., Zoletnik, V., Zychor, S., I, and JET Contributors
- Subjects
Jet (fluid) ,Surface analysis ,Materials science ,Divertor ,JET-ILW ,Material deposition ,Material erosion ,Nuclear engineering ,Condensed Matter Physics ,01 natural sciences ,Atomic and Molecular Physics, and Optics ,010305 fluids & plasmas ,13. Climate action ,Material Erosion ,0103 physical sciences ,Erosion ,010306 general physics ,Deposition (chemistry) ,Mathematical Physics - Abstract
Erosion of plasma-facing materials and successive transport and redeposition of eroded material are crucial processes determining the lifetime of plasma-facing components and the trapped tritium inventory in redeposited material layers. Erosion and deposition in the JET divertor were studied during the second JET ITER-like wall campaign ILW-2 in 2013-2014 by using a poloidal row of specially prepared divertor marker tiles including the tungsten bulk tile 5. The marker tiles were analyzed using elastic backscattering with 3-4.5 MeV incident protons and nuclear reaction analysis using 0.8-4.5 MeV 3He ions before and after the campaign. The erosion/deposition pattern observed during ILW-2 is qualitatively comparable to the first campaign ILW-1 in 2011-2012: deposits consist mainly of beryllium with 5-20 at.% of carbon and oxygen and small amounts of Ni and W. The highest deposition with deposited layer thicknesses up to 30 μm per campaign is still observed on the upper and horizontal parts of the inner divertor. Outer divertor tiles 5, 6, 7 and 8 are net W erosion areas. The observed D inventory is roughly comparable to the inventory observed during ILW-1. The results obtained during ILW-2 therefore confirm the positive results observed in ILW-1 with respect to reduced material deposition and hydrogen isotopes retention in the divertor.
- Published
- 2017
- Full Text
- View/download PDF
8. Overview of fuel inventory in JET with the ITER-like wall
- Author
-
Widdowson, A., Coad, J. P., Alves, E., Baron-Wiechec, A., Barradas, N. P., Brezinsek, S., Catarino, N., Corregidor, V., Heinola, K., Koivuranta, S., Krat, S., Lahtinen, A., Likonen, J., Matthews, G. F., Mayer, M., Petersson, P., Litaudon, Rubel M., Abduallev, X., Abhangi, S., Abreu, M., Afzal, P., Aggarwal, M., Ahlgren, K. M., Ahn, T., J. H., Aho, Mantila, Aiba, L., Airila, N., Albanese, M., Aldred, R., Alegre, V., Alessi, D., Aleynikov, E., Alfier, P., Alberto, Alkseev, Allinson, A., Alper, M., Alves, B., Ambrosino, E., Ambrosino, G., Amicucci, R., Amosov, L., Andersson, Sundã©n, Angelone, E., Anghel, M., Angioni, M., Appel, C., Appelbee, L., Arena, C., Ariola, P., Arnichand, M., Arshad, H., Ash, S., Ashikawa, A., Aslanyan, N., Asunta, V., Auriemma, O., Fulvio, Austin, Avotina, Y., Axton, L., Ayres, M. D., Bacharis, C., Baciero, M., Baiã¡o, A., Bailey, D., Baker, S., Balboa, A., Balden, I., Balshaw, M., Bament, N., Banks, R., Baranov, J. W., Barnard, Y. F., Barnes, M. A., Barnes, D., Barnsley, M., Baron, Wiechec, Barrera, Orte, Baruzzo, L., Matteo, Basiuk, Bassan, V., Bastow, M., Batista, R., Batistoni, A., Baughan, P., Bauvir, R., Baylor, B., Bazylev, L., Beal, B., Beaumont, J., Beckers, P. S., Beckett, M., Becoulet, B., Bekris, A., Beldishevski, N., Bell, M., Belli, K., Bellinger, F., Belonohy, M., Ben, Ayed, Benterman, N., Bergsã¥ker, N. A., Bernardo, H., Bernert, J., Berry, M., Bertalot, M., Besliu, L., Beurskens, C., Bieg, M., Bielecki, B., Biewer, J., Bigi, T., Bã¬lkovã¡, M., Binda, P., Bisoffi, F., Bizarro, A., Bjã¶rkas, J. P. S., Blackburn, C., Blackman, J., Blackman, K., Blanchard, T. R., Blatchford, P., Bobkov, P., Boboc, V., Bodnã¡r, A., Bogar, G., Bolshakova, O., Bolzonella, I., Tommaso, Bonanomi, Bonelli, N., Boom, F., Booth, J., Borba, J., Borodin, D., Borodkina, D., Botrugno, I., Bottereau, A., Boulting, C., Bourdelle, P., Bowden, C., Bower, M., Bowman, C., Boyce, C., Boyd, T., Boyer, C., Bradshaw, H. J., Braic, J. M. A., Bravanec, V., Breizman, R., Bremond, B., Brennan, S., Breton, P. D., Brett, S., Brezinsek, A., Bright, S., Brix, M. D. J., Broeckx, M., Brombin, W., Matteo, Broså‚awski, Brown, A., Brown, D. P. D., Bruno, M., Bucalossi, E., Buch, J., Buchanan, J., Buckley, J., Budny, M. A., Bufferand, R., Bulman, H., Bulmer, M., Bunting, N., Buratti, P., Burckhart, P., Buscarino, A., Busse, A., Butler, A., Bykov, N. K., Byrne, I., Cahyna, J., Calabrã², P., Calvo, G., Camenen, I., Camp, Y., Campling, P., Cane, D. C., Cannas, J., Capel, B., Card, A. J., Cardinali, P. J., Carman, A., Carr, P., Carralero, M., Carraro, D., Carvalho, L., Carvalho, B. B., Carvalho, I., Casson, P., Castaldo, F. J., Catarino, C., Caumont, N., Causa, J., Cavazzana, F., Cave, Ayland, Cavinato, K., Cecconello, M., Ceccuzzi, M., Cecil, S., Cenedese, E., Angelo, Cesario, Challis, R., Chandler, C. D., Chandra, M., Chang, D., Chankin, C. S., Chapman, A., Chapman, I. T., Chernyshova, S. C., Chitarin, M., Giuseppe, Ciraolo, Ciric, G., Citrin, D., Clairet, J., Clark, F., Clark, E., Clarkson, M., Clatworthy, R., Clements, D., Cleverly, C., Coad, M., Coates, J. P., Cobalt, P. A., Coccorese, A., Cocilovo, V., Coda, V., Coelho, S., Coenen, R., Coffey, J. W., Colas, I., Collins, L., Conka, S., Conroy, D., Conway, S., Coombs, N., Cooper, D., Corradino, S. R., Corre, C., Corrigan, Y., Cortes, G., Coster, S., Couchman, D., Cox, A. S., Craciunescu, M. P., Cramp, T., Craven, S., Crisanti, R., Croci, F., Croft, G., Crombã©, D., Crowe, K., Cruz, R., Cseh, N., Cufar, G., Cullen, A., Curuia, A., Czarnecka, M., Dabirikhah, A., Dalgliesh, H., Dalley, P., Dankowski, S., Darrow, J., Davies, D., Davis, O., Day, W., Day, C., I. E., Bock, De, Castro, De, De La Cal, De La Luna, Masi, De, Pablos, De, J. L., Temmerman, De, Tommasi, De, Vries, De, Deakin, P., Deane, K., Degli, Agostini, Dejarnac, F., Delabie, R., Den, Harder, Dendy, N., Denis, R. O., Denner, J., Devaux, P., Devynck, S., Maio, Di, Siena, Di, Troia, Di, Dinca, C., D'Inca, P., Ding, R., Dittmar, B., Doerk, T., Doerner, H., Donnã©, R. P., Dorling, T., S. E., Dormido, Canto, Doswon, S., Douai, S., Doyle, D., Drenik, P. T., Drewelow, A., Drews, P., Duckworth, P., Dumont, P. h., Dumortier, R., Dunai, P., Dunne, D., Äžuran, M., Durodiã©, I., Dutta, F., Duval, P., Dux, B. P., Dylst, R., Dzysiuk, K., Edappala, N., Edmond, P. V., Edwards, J., Edwards, A. M., Eich, J., Ekedahl, T. h., Jorf, El, Elsmore, R., Enachescu, C. G., Ericsson, M., Eriksson, G., Eriksson, F., Eriksson, J., Esposito, L. G., Esquembri, B., Esser, S., Esteve, H. G., Evans, D., Evans, B., Evison, G. E., Ewart, G., Fagan, G. D., Faitsch, D., Falie, M., Fanni, D., Fasoli, A., Faustin, A., Fawlk, J. M., Fazendeiro, N., Fedorczak, L., Felton, N., Fenton, R. C., Fernades, K., Fernandes, A., Ferreira, H., Fessey, J., Fã©vrier, J. A., Ficker, O., Field, O., Fietz, A., Figueiredo, S., Figueiredo, A., Fil, J., Finburg, A., Firdaouss, P., Fischer, M., Fittill, U., Fitzgerald, L., Flammini, M., Flanagan, D., Fleming, J., Flinders, C., Fonnesu, K., Fontdecaba, N., Formisano, J. M., Forsythe, A., Fortuna, L., Fortuna, Zalesna, Fortune, E., Foster, M., Franke, S., Franklin, T., Frasca, T., Frassinetti, M., Freisinger, L., Fresa, M., Frigione, R., Fuchs, D., Fuller, V., Futatani, D., Fyvie, S., Gã¡l, J., Galassi, K., Gaå‚azka, D., Galdon, Quiroga, Gallagher, J., Gallart, J., Galvã¡o, D., Gao, R., Gao, X., Garcia, Y., Garcia, Carrasco, Garcã¬a, Muã±oz, Gardarein, M., Garzotti, J. L., Gaudio, L., Gauthier, P., Gear, E., Gee, D. F., Geiger, S. J., Gelfusa, B., Gerasimov, M., Gervasini, S., Gethins, G., Ghani, M., Ghate, Z., Gherendi, M., Giacalone, M., Giacomelli, J. C., Gibson, L., Giegerich, C. S., Gil, T., Gil, C., Gilligan, L., Gin, S., Giovannozzi, D., Girardo, E., Giroud, J. B., Giruzzi, C., Gerardo, Glã¶ggler, Godwin, S., Goff, J., Gohil, J., Goloborod'Ko, P., Gomes, V., Goncalves, R., Goniche, B., Goodliffe, M., Goodyear, M., Gorini, A., Gosk, G., Goulding, M., Goussarov, R., Gowland, A., Graham, R., Graham, B., Graves, M. E., Grazier, J. P., Grazier, N., Green, P., Greuner, N. R., Grierson, H., Griph, B., Grisolia, F. S., Grist, C., Groth, D., Grove, M., Grundy, R., Grzonka, C. N., Guard, J., Guã©rard, D., Guillemaut, C., Guirlet, C., Gurl, R., Utoh, C., Hackett, H. H., Hacquin, L. J., Hagar, S., Hager, A., Hakola, R., Halitovs, A., Hall, M., S. J., Hallworth, Cook, S. P., Hamlyn, Harris, Hammond, C., Harrington, K., Harrison, C., Harting, J., Hasenbeck, D., Hatano, F., Hatch, Y., Haupt, D. R., Hawes, T. D. V., Hawkes, J., Hawkins, N. C., Hawkins, J., Haydon, P., Hayter, P. W., Hazel, N., Heesterman, S., Heinola, P. J. L., Hellesen, K., Hellsten, C., Helou, T., Hemming, W., Hender, O. N., Henderson, T. C., Henderson, M., Henriques, S. S., Hepple, R., Hermon, D., Hertout, G., Hidalgo, P., Highcock, C., Hill, E. G., Hillairet, M., Hillesheim, J., Hillis, J., Hizanidis, D., Hjalmarsson, K., Hobirk, A., Hodille, J., Hogben, E., Hogeweij, C. H. A., Hollingsworth, G. M. D., Hollis, A., Homfray, S., Horã¡äek, D. A., Hornung, J., Horton, G., Horton, A. R., Horvath, L. D., Hotchin, L., Hough, S. P., Howarth, M. R., Hubbard, P. J., Huber, A., Huddleston, V., Hughes, T. M., Huijsmans, M., Hunter, G. T. A., Huynh, C. L., Hynes, P., Iglesias, A. M., Imazawa, D., Imbeaux, N., Imrã¬å¡ek, F., Incelli, M., Innocente, M., Irishkin, P., Ivanova, Stanik, Jachmich, I., Jacobsen, S., Jacquet, A. S., Jansons, P., Jardin, J., Jã¤rvinen, A., Jaulmes, A., Jednorã³g, F., Jenkins, S., Jeong, I., Jepu, C., Joffrin, I., Johnson, E., Johnson, R., Johnston, T., Jane, Joita, Jones, L., Jones, G., Hoshino, T. T. C., Kallenbach, K. K., Kamiya, A., Kaniewski, K., Kantor, J., Kappatou, A., Karhunen, A., Karkinsky, J., Karnowska, D., Kaufman, I., Kaveney, M., Kazakov, G., Kazantzidis, Y., Keeling, V., Keenan, D. L., Keep, T., Kempenaars, J., Kennedy, M., Kenny, C., Kent, D., Kent, J., Khilkevich, O. N., Kim, E., Kim, H. T., Kinch, H. S., King, A., King, C., King, D., Kinna, R. F., Kiptily, D. J., Kirk, V., Kirov, A., Kirschner, K., Kizane, A., Klepper, G., Klix, C., Knight, A., Knipe, P., Knott, S. J., Kobuchi, S., Kã¶chl, T., Kocsis, F., Kodeli, G., Kogan, I., Kogut, L., Koivuranta, D., Kominis, S., Kã¶ppen, Y., Kos, M., Koskela, B., Koslowski, T., Koubiti, H. R., Kovari, M., Kowalska, Strzè©ciwilk, Krasilnikov, E., Krasilnikov, A., Krawczyk, V., Kresina, N., Krieger, M., Krivska, K., Kruezi, A., Ksiaå¼ek, U., Kukushkin, I., Kundu, A., Kurki, Suonio, Kwak, T., Kwiatkowski, S., Kwon, R., Laguardia, O. J., Lahtinen, L., Laing, A., Lam, A., Lambertz, N., Lane, H. T., Lang, C., Lanthaler, P. T., Lapins, S., Lasa, J., Last, A., Åaszyå„ska, J. R., Lawless, E., Lawson, R., Lawson, A., Lazaros, K. D., Lazzaro, A., Leddy, E., Lee, J., Lefebvre, S., Leggate, X., Lehmann, H. J., Lehnen, J., Leichtle, M., Leichuer, D., Leipold, P., Lengar, F., Lennholm, I., Lerche, M., Lescinskis, E., Lesnoj, A., Letellier, S., Leyland, E., Leysen, M., Li, W., Liang, L., Likonen, Y., Linke, J., Linsmeier, J., Lipschultz, C. h., Liu, B., Liu, G., Schiavo, Lo, Loarer, V. P., Loarte, T., Lobel, A., Lomanowski, R. C., Lomas, B., Lã¶nnroth, P. J., Lã³pez, J., J. M., Lã³pez, Razola, Lorenzini, J., Losada, R., Lovell, U., Loving, J. J., Lowry, A. B., Luce, C., Lucock, T., Lukin, R. M. A., Luna, A., Lungaroni, C., Lungu, M., Lungu, C. P., Lunniss, M., Lupelli, A., Lyssoivan, I., Macdonald, A., Macheta, N., Maczewa, P., Magesh, K., Maget, B., Maggi, P., Maier, C., Mailloux, H., Makkonen, J., Makwana, T., Malaquias, R., Malizia, A., Manas, A., Manning, P., Manso, A., Mantica, M. E., Mantsinen, P., Manzanares, M., Maquet, A., Marandet, P. h., Marcenko, Y., Marchetto, N., Marchuk, C., Marinelli, O., Marinucci, M., Markoviä, M., Marocco, T., Marot, D., Marren, L., Marshal, C. A., Martin, R., Martin, A., Martìn De Aguilera, Martã¬nez, A., F. J., Martã¬n, Solã¬s, Martynova, J. R., Maruyama, Y., Masiello, S., Maslov, A., Matejcik, M., Mattei, S., Matthews, M., Maviglia, G. F., Mayer, F., Mayoral, M., M. L., May, Smith, Mazon, T., Mazzotta, D., Mcadams, C., Mccarthy, R., Mcclements, P. J., Mccormack, K. G., Mccullen, O., Mcdonald, P. A., Mcintosh, D., Mckean, S., Mckehon, R., Meadows, J., Meakins, R. C., Medina, A., Medland, F., Medley, M., Meigh, S., Meigs, S., Meisl, A. G., Meitner, G., Meneses, S., Menmuir, L., Mergia, S., Merrigan, K., Mertens, I. R., Meshchaninov, P. h., Messiaen, S., Meyer, A., Mianowski, H., Michling, S., Middleton, Gear, Miettunen, D., Militello, J., Militello, Asp, Miloshevsky, E., Mink, G., Minucci, F., Miyoshi, S., Mlynã¡å™, Y., Molina, J., Monakhov, D., Moneti, I., Mooney, M., Moradi, R., Mordijck, S., Moreira, S., Moreno, L., Moro, R., Morris, F., Morris, A. W., Moser, J., Mosher, L., Moulton, S., Murari, D., Muraro, A., Murphy, A., Asakura, S., N. N., Na, Nabais, Y. S., Naish, F., Nakano, R., Nardon, T., Naulin, E., Nave, V., Nedzelski, M. F. F., Nemtsev, I., Nespoli, G., Neto, F., Neu, A., Neverov, R., Newman, V. S., Nicholls, M., Nicolas, K. J., Nielsen, T., Nielsen, A. H., Nilsson, P., Nishijima, E., Noble, D., Nocente, C., Nodwell, M., Nordlund, D., Nordman, K., Nouailletas, H., Nunes, R., Oberkofler, I., Odupitan, M., Ogawa, T., O'Gorman, M. T., Okabayashi, T., Olney, M., Omolayo, R., O'Mullane, O., Ongena, M., Orsitto, J., Orszagh, F., Oswuigwe, J., Otin, B. I., Owen, R., Paccagnella, A., Pace, R., Pacella, N., Packer, D., Page, L. W., Pajuste, A., Palazzo, E., Pamela, S., Panja, S., Papp, S., Paprok, P., Parail, R., Park, V., Parra, Diaz, Parsons, F., Pasqualotto, M., Patel, R., Pathak, A., Paton, S., Patten, D., Pau, H., Pawelec, A., Paz, Soldan, Peackoc, C., Pearson, A., Pehkonen, I. J., Peluso, S. P., Penot, E., Pereira, C., Pereira, A., Pereira, Puglia, P. P., Perez Von Thun, Peruzzo, C., Peschanyi, S., Peterka, S., Petersson, M., Petravich, P., Petre, G., Petrella, A., Petrå¾ilka, N., Peysson, V., Pfefferlã©, Y., Philipps, D., Pillon, V., Pintsuk, M., Piovesan, G., Pires Dos Reis, Piron, Lidia, Pironti, A., Pisano, F., Pitts, R., Pizzo, F., Plyusnin, V., Pomaro, N., Pompilian, O. G., Pool, P. J., Popovichev, S., Porfiri, M. T., Porosnicu, C., Porton, M., Possnert, G., Potzel, S., Powell, T., Pozzi, J., Prajapati, V., Prakash, R., Prestopino, G., Price, D., Price, M., Price, R., Prior, P., Proudfoot, R., Pucella, G., Puglia, P., Puiatti, M. E., Pulley, D., Purahoo, K., Pã¼tterich, T. h., Rachlew, E., Rack, M., Ragona, R., Rainford, M. S. J., Rakha, A., Ramogida, G., Ranjan, S., Rapson, C. J., Rasmussen, J. J., Rathod, K., Rattã¡, G., Ratynskaia, S., Ravera, G., Rayner, C., Rebai, M., Reece, D., Reed, A., Rã©fy, D., Regan, B., Regaã±a, J., Reich, M., Reid, N., Reimold, F., Reinhart, M., Reinke, M., Reiser, D., Rendell, D., Reux, C., Reyes, Cortes, Reynolds, S. D. A., Riccardo, S., Richardson, V., Riddle, N., Rigamonti, K., Rimini, D., Risner, F. G., Riva, J., Roach, M., Robins, C., Robinson, R. J., Robinson, S. A., Robson, T., Roccella, D. W., Rodionov, R., Rodrigues, R., Rodriguez, P., Rohde, J., Romanelli, V., Romanelli, F., Romanelli, M., Romazanov, S., Rowe, J., Rubel, S., Rubinacci, M., Rubino, G., Ruchko, G., Ruiz, L., Ruset, M., Rzadkiewicz, C., Saarelma, J., Sabot, S., Safi, R., Sagar, E., Saibene, P., Saint, Laurent, Salewski, F., Salmi, M., Salmon, A., Salzedas, R., Samaddar, F., Samm, D., Sandiford, U., Santa, D., Santala, P., Santos, M. I. K., Santucci, B., Sartori, A., Sartori, F., Sauter, R., Scannell, O., Schlummer, R., Schmid, T., Schmidt, K., Schmuck, V., Schneider, S., Schã¶pf, M., Schwã¶rer, K., Scott, D., Sergienko, S. D., Sertoli, G., Shabbir, M., Sharapov, A., Shaw, S. E., Shaw, A., Sheikh, R., Shepherd, H., Shevelev, A., Shumack, A., Sias, A., Sibbald, G., Sieglin, M., Silburn, B., Silva, S., Silva, A., Simmons, C., Simpson, P. A., Simpson, Hutchinson, Sinha, J., Sipilã¤, A., Sips, S. K., Sirã©n, A. C. C., Sirinelli, P., Sjã¶strand, A., Skiba, H., Skilton, M., Slabkowska, R., Slade, K., Smith, B., Smith, N., Smith, P. G., Smith, R., Smithies, T. J., Snoj, M., Soare, L., Solano, S., Somers, E. R., Sommariva, A., Sonato, C., Piergiorgio, Sopplesa, Sousa, A., Sozzi, J., Spagnolo, C., Silvia, Spelzini, Spineanu, T., Stables, F., Stamatelatos, G., Stamp, I., Staniec, M. F., Stankå«nas, P., Stan, Sion, Stead, C., Stefanikova, M. J., Stepanov, E., Stephen, I., Stephen, A. V., Stevens, M., Stevens, A., Strachan, B. D., Strand, J., Strauss, P., Strã¶m, H. R., Stubbs, P., Studholme, G., Subba, W., Summers, F., Svensson, H. P., Åšwiderski, J., Szabolics, Å. ., Szawlowski, T., Szepesi, M., Suzuki, G., Tã¡l, T. T., Tala, B., Talbot, T., Talebzadeh, A. R., Taliercio, S., Cesare, Tamain, Tame, P., Tang, C., Tardocchi, W., Taroni, M., Taylor, L., Taylor, D., Tegnered, K. A., Telesca, D., Teplova, G., Terranova, N., David, Testa, Tholerus, D., Thomas, E., Thomas, J., Thomas, J. D., Thompson, P., Thompson, A., Thompson, C. A., Thorne, V. K., Thornton, L., Thrysã¸e, A., Tigwell, A. S., Tipton, P. A., Tiseanu, N., Tojo, I., Tokitani, H., Tolias, M., Tomeå¡, P., Tonner, M., Towndrow, P., Trimble, M., Tripsky, P., Tsalas, M., Tsavalas, M., Tskhakaya, Jun, Turner, D., Turner, I., Turnyanskiy, M. M., Tvalashvili, M., Tyrrell, G., Uccello, S. G. J., Abidin, Ul, Uljanovs, Z., Ulyatt, J., Urano, D., Uytdenhouwen, H., Vadgama, I., Valcarcel, A. P., Valentinuzzi, D., Valisa, M., Vallejos, Olivares, Valovic, P., Van De Mortel, Van, Eester, Van, Renterghem, Van, Rooij, Varje, G. J., Varoutis, J., Vartanian, S., Vasava, S., Vasilopoulou, K., Vega, T., Verdoolaege, J., Verhoeven, G., Verona, R., Verona, Rinati, Veshchev, G., Vianello, E., Vicente, N., Viezzer, J., Villari, E., Villone, S., Vincenzi, F., Pietro, Vinyar, Viola, I., Vitins, B., Vizvary, A., Vlad, Z., Voitsekhovitch, M., Vondrã¡äek, I., Vora, P., Vu, N., Pires De Sa, Wakeling, W. W., Waldon, B., Walkden, C. W. F., Walker, N., Walker, M., Walsh, R., Wang, M., Wang, E., Warder, N., Warren, S., Waterhouse, R. J., Watkins, J., Watts, N. W., Wauters, C., Weckmann, T., Weiland, A., Weisen, J., Weiszflog, H., Wellstood, M., West, C., Wheatley, A. T., Whetham, M. R., Whitehead, S., Whitehead, A. M., Widdowson, B. D., Wiesen, A. M., Wilkinson, S., Williams, J., Wilson, M., Wilson, A. R., Wilson, D. J., Wilson, H. R., Wischmeier, J., Withenshaw, M., Withycombe, G., Witts, A., Wood, D. M., Wood, D., Woodley, R., Wray, C., Wright, S., Wright, J., J. C., Wu, Wukitch, J., Wynn, S., Xu, A., Yadikin, T., Yanling, D., Yao, W., Yavorskij, L., Yoo, V., Young, M. G., Young, C., Young, D., Young, I. D., Zacks, R., Zagorski, J., Zaitsev, R., Zanino, F. S., Zarins, R., Zastrow, A., Zerbini, K. D., Zhang, M., Zhou, W., Zilli, Y., Zoita, E., Zoletnik, V., Zychor, S., I, and JET Contributors
- Subjects
Nuclear and High Energy Physics ,Jet (fluid) ,Hydrogen ,Plasma parameters ,JET ITER-like wall ,Divertor ,Nuclear engineering ,chemistry.chemical_element ,Condensed Matter Physics ,01 natural sciences ,fuel retention ,010305 fluids & plasmas ,material migration ,chemistry ,Sputtering ,visual_art ,0103 physical sciences ,visual_art.visual_art_medium ,Environmental science ,Tile ,010306 general physics - Abstract
Post mortem analyses of JET ITER-Like-Wall tiles and passive diagnostics have been completed after each of the first two campaigns (ILW-1 and ILW-2). They show that the global fuel inventory is still dominated by co-deposition; hence plasma parameters and sputtering processes affecting material migration influence the distribution of retained fuel. In particular, differences between results from the two campaigns may be attributed to a greater proportion of pulses run with strike points in the divertor corners, and having about 300 discharges in hydrogen at the end of ILW-2. Recessed and remote areas can contribute to fuel retention due to the larger areas involved, e.g. recessed main chamber walls, gaps in castellated Be main chamber tiles and material migration to remote divertor areas. The fuel retention and material migration due to the bulk W Tile 5 during ILW-1 are presented. Overall these tiles account for only a small percentage of the global accountancy for ILW-1.
- Published
- 2017
- Full Text
- View/download PDF
9. Systematische Entwicklung und Validierung einer Informationsbroschüre zur Harnleiterschienung und der assoziierten Morbidität
- Author
-
Abt, D., Betschart, P., Zumstein, V., Babst, C., Sauter, R., Schmid, H.-P., and Staubli, S.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Fragestellung: Im Vorfeld konnten wir zeigen, dass gründliche Patientenaufklärung mit einer reduzierten Morbidität durch Harnleiterschienung assoziiert ist. Das Ziel unserer Arbeit war es, basierend auf etablierten psychometrischen und statistischen Methoden, einen Algorithmus zur systematischen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 43. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung
- Published
- 2017
10. P2575Comparison of deep sedation with general anesthesia in patients undergoing percutaneous mitral valve repair (PMVR)
- Author
-
Patzelt, J, primary, Ulrich, M, additional, Magunia, H F, additional, Sauter, R, additional, Droppa, M, additional, Jorbenadze, R, additional, Becker, A S, additional, Walker, T, additional, Von Bardeleben, R S, additional, Grasshoff, C, additional, Rosenberger, P, additional, Gawaz, M, additional, Seizer, P, additional, and Langer, H F, additional
- Published
- 2018
- Full Text
- View/download PDF
11. FRI0456 Predictors for disease worsening defined by organ failure in diffuse systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis
- Author
-
Becker, M.O., primary, Graf, N., additional, Sauter, R., additional, Allanore, Y., additional, Curram, J., additional, Denton, C., additional, Khanna, D., additional, Matucci-Cerinic, M., additional, Pena, J., additional, Pope, J.E., additional, and Distler, O., additional
- Published
- 2018
- Full Text
- View/download PDF
12. MeV-range velocity-space tomography from gamma-ray and neutron emission spectrometry measurements at JET
- Author
-
Salewski, M., Nocente, M., Jacobsen, A. S., Binda, F., Cazzaniga, C., Ericsson, G., Eriksson, J., Gorini, G., Hellesen, C., Hjalmarsson, A., Kiptily, V. G., Koskela, T., Korsholm, S. B., Kurki-Suonio, T., Leipold, F., Madsen, J., Moseev, D., Nielsen, S. K., Rasmussen, J., Schneider, M., Sharapov, S. E., Stejner, M., Litaudon, Tardocchi M., Abduallev, X., Abhangi, S., Abreu, M., Afzal, P., Aggarwal, M., Ahlgren, K. M., Ahn, T., J. H., Aho, Mantila, Aiba, L., Airila, N., Albanese, M., Aldred, R., Alegre, V., Alessi, D., Aleynikov, E., Alfier, P., Alberto, Alkseev, Allinson, A., Alper, M., Alves, B., Ambrosino, E., Ambrosino, G., Amicucci, R., Amosov, L., Andersson, Sundã©n, Angelone, E., Anghel, M., Angioni, M., Appel, C., Appelbee, L., Arena, C., Ariola, P., Arnichand, M., Arshad, H., Ash, S., Ashikawa, A., Aslanyan, N., Asunta, V., Auriemma, O., Fulvio, Austin, Avotina, Y., Axton, L., Ayres, M. D., Bacharis, C., Baciero, M., Baiã¡o, A., Bailey, D., Baker, S., Balboa, A., Balden, I., Balshaw, M., Bament, N., Banks, R., Baranov, J. W., Barnard, Y. F., Barnes, M. A., Barnes, D., Barnsley, M., Baron, Wiechec, Barrera, Orte, Baruzzo, L., Matteo, Basiuk, Bassan, V., Bastow, M., Batista, R., Batistoni, A., Baughan, P., Bauvir, R., Baylor, B., Bazylev, L., Beal, B., Beaumont, J., Beckers, P. S., Beckett, M., Becoulet, B., Bekris, A., Beldishevski, N., Bell, M., Belli, K., Bellinger, F., Belonohy, M., Ben, Ayed, Benterman, N., Bergsã¥ker, N. A., Bernardo, H., Bernert, J., Berry, M., Bertalot, M., Besliu, L., Beurskens, C., Bieg, M., Bielecki, B., Biewer, J., Bigi, T., Bã¬lkovã¡, M., Binda, P., Bisoffi, F., Bizarro, A., Bjã¶rkas, J. P. S., Blackburn, C., Blackman, J., Blackman, K., Blanchard, T. R., Blatchford, P., Bobkov, P., Boboc, V., Bodnã¡r, A., Bogar, G., Bolshakova, O., Bolzonella, I., Tommaso, Bonanomi, Bonelli, N., Boom, F., Booth, J., Borba, J., Borodin, D., Borodkina, D., Botrugno, I., Bottereau, A., Boulting, C., Bourdelle, P., Bowden, C., Bower, M., Bowman, C., Boyce, C., Boyd, T., Boyer, C., Bradshaw, H. J., Braic, J. M. A., Bravanec, V., Breizman, R., Bremond, B., Brennan, S., Breton, P. D., Brett, S., Brezinsek, A., Bright, S., Brix, M. D. J., Broeckx, M., Brombin, W., Matteo, Broså‚awski, Brown, A., Brown, D. P. D., Bruno, M., Bucalossi, E., Buch, J., Buchanan, J., Buckley, J., Budny, M. A., Bufferand, R., Bulman, H., Bulmer, M., Bunting, N., Buratti, P., Burckhart, P., Buscarino, A., Busse, A., Butler, A., Bykov, N. K., Byrne, I., Cahyna, J., Calabrã², P., Calvo, G., Camenen, I., Camp, Y., Campling, P., Cane, D. C., Cannas, J., Capel, B., Card, A. J., Cardinali, P. J., Carman, A., Carr, P., Carralero, M., Carraro, D., Carvalho, L., Carvalho, B. B., Carvalho, I., Casson, P., Castaldo, F. J., Catarino, C., Caumont, N., Causa, J., Cavazzana, F., Cave, Ayland, Cavinato, K., Cecconello, M., Ceccuzzi, M., Cecil, S., Cenedese, E., Angelo, Cesario, Challis, R., Chandler, C. D., Chandra, M., Chang, D., Chankin, C. S., Chapman, A., Chapman, I. T., Chernyshova, S. C., Chitarin, M., Giuseppe, Ciraolo, Ciric, G., Citrin, D., Clairet, J., Clark, F., Clark, E., Clarkson, M., Clatworthy, R., Clements, D., Cleverly, C., Coad, M., Coates, J. P., Cobalt, P. A., Coccorese, A., Cocilovo, V., Coda, V., Coelho, S., Coenen, R., Coffey, J. W., Colas, I., Collins, L., Conka, S., Conroy, D., Conway, S., Coombs, N., Cooper, D., Corradino, S. R., Corre, C., Corrigan, Y., Cortes, G., Coster, S., Couchman, D., Cox, A. S., Craciunescu, M. P., Cramp, T., Craven, S., Crisanti, R., Croci, F., Croft, G., Crombã©, D., Crowe, K., Cruz, R., Cseh, N., Cufar, G., Cullen, A., Curuia, A., Czarnecka, M., Dabirikhah, A., Dalgliesh, H., Dalley, P., Dankowski, S., Darrow, J., Davies, D., Davis, O., Day, W., Day, C., I. E., Bock, De, Castro, De, De La Cal, De La Luna, Masi, De, Pablos, De, J. L., Temmerman, De, Tommasi, De, Vries, De, Deakin, P., Deane, K., Degli, Agostini, Dejarnac, F., Delabie, R., Den, Harder, Dendy, N., Denis, R. O., Denner, J., Devaux, P., Devynck, S., Maio, Di, Siena, Di, Troia, Di, Dinca, C., D'Inca, P., Ding, R., Dittmar, B., Doerk, T., Doerner, H., Donnã©, R. P., Dorling, T., S. E., Dormido, Canto, Doswon, S., Douai, S., Doyle, D., Drenik, P. T., Drewelow, A., Drews, P., Duckworth, P., Dumont, P. h., Dumortier, R., Dunai, P., Dunne, D., Äžuran, M., Durodiã©, I., Dutta, F., Duval, P., Dux, B. P., Dylst, R., Dzysiuk, K., Edappala, N., Edmond, P. V., Edwards, J., Edwards, A. M., Eich, J., Ekedahl, T. h., Jorf, El, Elsmore, R., Enachescu, C. G., Ericsson, M., Eriksson, G., Eriksson, F., Esposito, L. G., Esquembri, B., Esser, S., Esteve, H. G., Evans, D., Evans, B., Evison, G. E., Ewart, G., Fagan, G. D., Faitsch, D., Falie, M., Fanni, D., Fasoli, A., Faustin, A., Fawlk, J. M., Fazendeiro, N., Fedorczak, L., Felton, N., Fenton, R. C., Fernades, K., Fernandes, A., Ferreira, H., Fessey, J., Fã©vrier, J. A., Ficker, O., Field, O., Fietz, A., Figueiredo, S., Figueiredo, A., Fil, J., Finburg, A., Firdaouss, P., Fischer, M., Fittill, U., Fitzgerald, L., Flammini, M., Flanagan, D., Fleming, J., Flinders, C., Fonnesu, K., Fontdecaba, N., Formisano, J. M., Forsythe, A., Fortuna, L., Fortuna, Zalesna, Fortune, E., Foster, M., Franke, S., Franklin, T., Frasca, T., Frassinetti, M., Freisinger, L., Fresa, M., Frigione, R., Fuchs, D., Fuller, V., Futatani, D., Fyvie, S., Gã¡l, J., Galassi, K., Gaå‚azka, D., Galdon, Quiroga, Gallagher, J., Gallart, J., Galvã¡o, D., Gao, R., Gao, X., Garcia, Y., Garcia, Carrasco, Garcã¬a, Muã±oz, Gardarein, M., Garzotti, J. L., Gaudio, L., Gauthier, P., Gear, E., Gee, D. F., Geiger, S. J., Gelfusa, B., Gerasimov, M., Gervasini, S., Gethins, G., Ghani, M., Ghate, Z., Gherendi, M., Giacalone, M., Giacomelli, J. C., Gibson, L., Giegerich, C. S., Gil, T., Gil, C., Gilligan, L., Gin, S., Giovannozzi, D., Girardo, E., Giroud, J. B., Giruzzi, C., Gerardo, Glã¶ggler, Godwin, S., Goff, J., Gohil, J., Goloborod'Ko, P., Gomes, V., Goncalves, R., Goniche, B., Goodliffe, M., Goodyear, M., Gorini, A., Gosk, G., Goulding, M., Goussarov, R., Gowland, A., Graham, R., Graham, B., Graves, M. E., Grazier, J. P., Grazier, N., Green, P., Greuner, N. R., Grierson, H., Griph, B., Grisolia, F. S., Grist, C., Groth, D., Grove, M., Grundy, R., Grzonka, C. N., Guard, J., Guã©rard, D., Guillemaut, C., Guirlet, C., Gurl, R., Utoh, C., Hackett, H. H., Hacquin, L. J., Hagar, S., Hager, A., Hakola, R., Halitovs, A., Hall, M., S. J., Hallworth, Cook, S. P., Hamlyn, Harris, Hammond, C., Harrington, K., Harrison, C., Harting, J., Hasenbeck, D., Hatano, F., Hatch, Y., Haupt, D. R., Hawes, T. D. V., Hawkes, J., Hawkins, N. C., Hawkins, J., Haydon, P., Hayter, P. W., Hazel, N., Heesterman, S., Heinola, P. J. L., Hellesen, K., Hellsten, C., Helou, T., Hemming, W., Hender, O. N., Henderson, T. C., Henderson, M., Henriques, S. S., Hepple, R., Hermon, D., Hertout, G., Hidalgo, P., Highcock, C., Hill, E. G., Hillairet, M., Hillesheim, J., Hillis, J., Hizanidis, D., Hjalmarsson, K., Hobirk, A., Hodille, J., Hogben, E., Hogeweij, C. H. A., Hollingsworth, G. M. D., Hollis, A., Homfray, S., Horã¡äek, D. A., Hornung, J., Horton, G., Horton, A. R., Horvath, L. D., Hotchin, L., Hough, S. P., Howarth, M. R., Hubbard, P. J., Huber, A., Huddleston, V., Hughes, T. M., Huijsmans, M., Hunter, G. T. A., Huynh, C. L., Hynes, P., Iglesias, A. M., Imazawa, D., Imbeaux, N., Imrã¬å¡ek, F., Incelli, M., Innocente, M., Irishkin, P., Ivanova, Stanik, Jachmich, I., Jacobsen, S., Jacquet, A. S., Jansons, P., Jardin, J., Jã¤rvinen, A., Jaulmes, A., Jednorã³g, F., Jenkins, S., Jeong, I., Jepu, C., Joffrin, I., Johnson, E., Johnson, R., Johnston, T., Jane, Joita, Jones, L., Jones, G., Hoshino, T. T. C., Kallenbach, K. K., Kamiya, A., Kaniewski, K., Kantor, J., Kappatou, A., Karhunen, A., Karkinsky, J., Karnowska, D., Kaufman, I., Kaveney, M., Kazakov, G., Kazantzidis, Y., Keeling, V., Keenan, D. L., Keep, T., Kempenaars, J., Kennedy, M., Kenny, C., Kent, D., Kent, J., Khilkevich, O. N., Kim, E., Kim, H. T., Kinch, H. S., King, A., King, C., King, D., Kinna, R. F., Kiptily, D. J., Kirk, V., Kirov, A., Kirschner, K., Kizane, A., Klepper, G., Klix, C., Knight, A., Knipe, P., Knott, S. J., Kobuchi, S., Kã¶chl, T., Kocsis, F., Kodeli, G., Kogan, I., Kogut, L., Koivuranta, D., Kominis, S., Kã¶ppen, Y., Kos, M., Koskela, B., Koslowski, T., Koubiti, H. R., Kovari, M., Kowalska, Strzè©ciwilk, Krasilnikov, E., Krasilnikov, A., Krawczyk, V., Kresina, N., Krieger, M., Krivska, K., Kruezi, A., Ksiaå¼ek, U., Kukushkin, I., Kundu, A., Kurki, Suonio, Kwak, T., Kwiatkowski, S., Kwon, R., Laguardia, O. J., Lahtinen, L., Laing, A., Lam, A., Lambertz, N., Lane, H. T., Lang, C., Lanthaler, P. T., Lapins, S., Lasa, J., Last, A., Åaszyå„ska, J. R., Lawless, E., Lawson, R., Lawson, A., Lazaros, K. D., Lazzaro, A., Leddy, E., Lee, J., Lefebvre, S., Leggate, X., Lehmann, H. J., Lehnen, J., Leichtle, M., Leichuer, D., Leipold, P., Lengar, F., Lennholm, I., Lerche, M., Lescinskis, E., Lesnoj, A., Letellier, S., Leyland, E., Leysen, M., Li, W., Liang, L., Likonen, Y., Linke, J., Linsmeier, J., Lipschultz, C. h., Liu, B., Liu, G., Schiavo, Lo, Loarer, V. P., Loarte, T., Lobel, A., Lomanowski, R. C., Lomas, B., Lã¶nnroth, P. J., Lã³pez, J., J. M., Lã³pez, Razola, Lorenzini, J., Losada, R., Lovell, U., Loving, J. J., Lowry, A. B., Luce, C., Lucock, T., Lukin, R. M. A., Luna, A., Lungaroni, C., Lungu, M., Lungu, C. P., Lunniss, M., Lupelli, A., Lyssoivan, I., Macdonald, A., Macheta, N., Maczewa, P., Magesh, K., Maget, B., Maggi, P., Maier, C., Mailloux, H., Makkonen, J., Makwana, T., Malaquias, R., Malizia, A., Manas, A., Manning, P., Manso, A., Mantica, M. E., Mantsinen, P., Manzanares, M., Maquet, A., Marandet, P. h., Marcenko, Y., Marchetto, N., Marchuk, C., Marinelli, O., Marinucci, M., Markoviä, M., Marocco, T., Marot, D., Marren, L., Marshal, C. A., Martin, R., Martin, A., Martìn De Aguilera, Martã¬nez, A., F. J., Martã¬n, Solã¬s, Martynova, J. R., Maruyama, Y., Masiello, S., Maslov, A., Matejcik, M., Mattei, S., Matthews, M., Maviglia, G. F., Mayer, F., Mayoral, M., M. L., May, Smith, Mazon, T., Mazzotta, D., Mcadams, C., Mccarthy, R., Mcclements, P. J., Mccormack, K. G., Mccullen, O., Mcdonald, P. A., Mcintosh, D., Mckean, S., Mckehon, R., Meadows, J., Meakins, R. C., Medina, A., Medland, F., Medley, M., Meigh, S., Meigs, S., Meisl, A. G., Meitner, G., Meneses, S., Menmuir, L., Mergia, S., Merrigan, K., Mertens, I. R., Meshchaninov, P. h., Messiaen, S., Meyer, A., Mianowski, H., Michling, S., Middleton, Gear, Miettunen, D., Militello, J., Militello, Asp, Miloshevsky, E., Mink, G., Minucci, F., Miyoshi, S., Mlynã¡å™, Y., Molina, J., Monakhov, D., Moneti, I., Mooney, M., Moradi, R., Mordijck, S., Moreira, S., Moreno, L., Moro, R., Morris, F., Morris, A. W., Moser, J., Mosher, L., Moulton, S., Murari, D., Muraro, A., Murphy, A., Asakura, S., N. N., Na, Nabais, Y. S., Naish, F., Nakano, R., Nardon, T., Naulin, E., Nave, V., Nedzelski, M. F. F., Nemtsev, I., Nespoli, G., Neto, F., Neu, A., Neverov, R., Newman, V. S., Nicholls, M., Nicolas, K. J., Nielsen, T., Nielsen, A. H., Nilsson, P., Nishijima, E., Noble, D., Nocente, C., Nodwell, M., Nordlund, D., Nordman, K., Nouailletas, H., Nunes, R., Oberkofler, I., Odupitan, M., Ogawa, T., O'Gorman, M. T., Okabayashi, T., Olney, M., Omolayo, R., O'Mullane, O., Ongena, M., Orsitto, J., Orszagh, F., Oswuigwe, J., Otin, B. I., Owen, R., Paccagnella, A., Pace, R., Pacella, N., Packer, D., Page, L. W., Pajuste, A., Palazzo, E., Pamela, S., Panja, S., Papp, S., Paprok, P., Parail, R., Park, V., Parra, Diaz, Parsons, F., Pasqualotto, M., Patel, R., Pathak, A., Paton, S., Patten, D., Pau, H., Pawelec, A., Paz, Soldan, Peackoc, C., Pearson, A., Pehkonen, I. J., Peluso, S. P., Penot, E., Pereira, C., Pereira, A., Pereira, Puglia, P. P., Perez Von Thun, Peruzzo, C., Peschanyi, S., Peterka, S., Petersson, M., Petravich, P., Petre, G., Petrella, A., Petrå¾ilka, N., Peysson, V., Pfefferlã©, Y., Philipps, D., Pillon, V., Pintsuk, M., Piovesan, G., Pires Dos Reis, Piron, Lidia, Pironti, A., Pisano, F., Pitts, R., Pizzo, F., Plyusnin, V., Pomaro, N., Pompilian, O. G., Pool, P. J., Popovichev, S., Porfiri, M. T., Porosnicu, C., Porton, M., Possnert, G., Potzel, S., Powell, T., Pozzi, J., Prajapati, V., Prakash, R., Prestopino, G., Price, D., Price, M., Price, R., Prior, P., Proudfoot, R., Pucella, G., Puglia, P., Puiatti, M. E., Pulley, D., Purahoo, K., Pã¼tterich, T. h., Rachlew, E., Rack, M., Ragona, R., Rainford, M. S. J., Rakha, A., Ramogida, G., Ranjan, S., Rapson, C. J., Rasmussen, J. J., Rathod, K., Rattã¡, G., Ratynskaia, S., Ravera, G., Rayner, C., Rebai, M., Reece, D., Reed, A., Rã©fy, D., Regan, B., Regaã±a, J., Reich, M., Reid, N., Reimold, F., Reinhart, M., Reinke, M., Reiser, D., Rendell, D., Reux, C., Reyes, Cortes, Reynolds, S. D. A., Riccardo, S., Richardson, V., Riddle, N., Rigamonti, K., Rimini, D., Risner, F. G., Riva, J., Roach, M., Robins, C., Robinson, R. J., Robinson, S. A., Robson, T., Roccella, D. W., Rodionov, R., Rodrigues, R., Rodriguez, P., Rohde, J., Romanelli, V., Romanelli, F., Romanelli, M., Romazanov, S., Rowe, J., Rubel, S., Rubinacci, M., Rubino, G., Ruchko, G., Ruiz, L., Ruset, M., Rzadkiewicz, C., Saarelma, J., Sabot, S., Safi, R., Sagar, E., Saibene, P., Saint, Laurent, Salewski, F., Salmi, M., Salmon, A., Salzedas, R., Samaddar, F., Samm, D., Sandiford, U., Santa, D., Santala, P., Santos, M. I. K., Santucci, B., Sartori, A., Sartori, F., Sauter, R., Scannell, O., Schlummer, R., Schmid, T., Schmidt, K., Schmuck, V., Schneider, S., Schã¶pf, M., Schwã¶rer, K., Scott, D., Sergienko, S. D., Sertoli, G., Shabbir, M., Sharapov, A., Shaw, S. E., Shaw, A., Sheikh, R., Shepherd, H., Shevelev, A., Shumack, A., Sias, A., Sibbald, G., Sieglin, M., Silburn, B., Silva, S., Silva, A., Simmons, C., Simpson, P. A., Simpson, Hutchinson, Sinha, J., Sipilã¤, A., Sips, S. K., Sirã©n, A. C. C., Sirinelli, P., Sjã¶strand, A., Skiba, H., Skilton, M., Slabkowska, R., Slade, K., Smith, B., Smith, N., Smith, P. G., Smith, R., Smithies, T. J., Snoj, M., Soare, L., Solano, S., Somers, E. R., Sommariva, A., Sonato, C., Piergiorgio, Sopplesa, Sousa, A., Sozzi, J., Spagnolo, C., Silvia, Spelzini, Spineanu, T., Stables, F., Stamatelatos, G., Stamp, I., Staniec, M. F., Stankå«nas, P., Stan, Sion, Stead, C., Stefanikova, M. J., Stepanov, E., Stephen, I., Stephen, A. V., Stevens, M., Stevens, A., Strachan, B. D., Strand, J., Strauss, P., Strã¶m, H. R., Stubbs, P., Studholme, G., Subba, W., Summers, F., Svensson, H. P., Åšwiderski, J., Szabolics, Å. ., Szawlowski, T., Szepesi, M., Suzuki, G., Tã¡l, T. T., Tala, B., Talbot, T., Talebzadeh, A. R., Taliercio, S., Cesare, Tamain, Tame, P., Tang, C., Tardocchi, W., Taroni, M., Taylor, L., Taylor, D., Tegnered, K. A., Telesca, D., Teplova, G., Terranova, N., David, Testa, Tholerus, D., Thomas, E., Thomas, J., Thomas, J. D., Thompson, P., Thompson, A., Thompson, C. A., Thorne, V. K., Thornton, L., Thrysã¸e, A., Tigwell, A. S., Tipton, P. A., Tiseanu, N., Tojo, I., Tokitani, H., Tolias, M., Tomeå¡, P., Tonner, M., Towndrow, P., Trimble, M., Tripsky, P., Tsalas, M., Tsavalas, M., Tskhakaya, Jun, Turner, D., Turner, I., Turnyanskiy, M. M., Tvalashvili, M., Tyrrell, G., Uccello, S. G. J., Abidin, Ul, Uljanovs, Z., Ulyatt, J., Urano, D., Uytdenhouwen, H., Vadgama, I., Valcarcel, A. P., Valentinuzzi, D., Valisa, M., Vallejos, Olivares, Valovic, P., Van De Mortel, Van, Eester, Van, Renterghem, Van, Rooij, Varje, G. J., Varoutis, J., Vartanian, S., Vasava, S., Vasilopoulou, K., Vega, T., Verdoolaege, J., Verhoeven, G., Verona, R., Verona, Rinati, Veshchev, G., Vianello, E., Vicente, N., Viezzer, J., Villari, E., Villone, S., Vincenzi, F., Pietro, Vinyar, Viola, I., Vitins, B., Vizvary, A., Vlad, Z., Voitsekhovitch, M., Vondrã¡äek, I., Vora, P., Vu, N., Pires De Sa, Wakeling, W. W., Waldon, B., Walkden, C. W. F., Walker, N., Walker, M., Walsh, R., Wang, M., Wang, E., Warder, N., Warren, S., Waterhouse, R. J., Watkins, J., Watts, N. W., Wauters, C., Weckmann, T., Weiland, A., Weisen, J., Weiszflog, H., Wellstood, M., West, C., Wheatley, A. T., Whetham, M. R., Whitehead, S., Whitehead, A. M., Widdowson, B. D., Wiesen, A. M., Wilkinson, S., Williams, J., Wilson, M., Wilson, A. R., Wilson, D. J., Wilson, H. R., Wischmeier, J., Withenshaw, M., Withycombe, G., Witts, A., Wood, D. M., Wood, D., Woodley, R., Wray, C., Wright, S., Wright, J., J. C., Wu, Wukitch, J., Wynn, S., Xu, A., Yadikin, T., Yanling, D., Yao, W., Yavorskij, L., Yoo, V., Young, M. G., Young, C., Young, D., Young, I. D., Zacks, R., Zagorski, J., Zaitsev, R., Zanino, F. S., Zarins, R., Zastrow, A., Zerbini, K. D., Zhang, M., Zhou, W., Zilli, Y., Zoita, E., Zoletnik, V., Zychor, S., I, JET Contributors, Salewski, M, Nocente, M, Jacobsen, A, Binda, F, Cazzaniga, C, Ericsson, G, Eriksson, J, Gorini, G, Hellesen, C, Hjalmarsson, A, Kiptily, V, Koskela, T, Korsholm, S, Kurki Suonio, T, Leipold, F, Madsen, J, Moseev, D, Nielsen, S, Rasmussen, J, Schneider, M, Sharapov, S, Stejner, M, and Tardocchi, M
- Subjects
Nuclear and High Energy Physics ,gamma-ray spectrometry ,Neutron emission ,Fluids & Plasmas ,Astrophysics::High Energy Astrophysical Phenomena ,Nuclear Theory ,01 natural sciences ,7. Clean energy ,Atomic ,010305 fluids & plasmas ,Ion ,Nuclear physics ,Particle and Plasma Physics ,Physics::Plasma Physics ,0103 physical sciences ,fast ion ,γ-ray spectrometry ,Neutron ,Nuclear ,Emission spectrum ,fast ions ,010306 general physics ,Nuclear Experiment ,tokamak ,Nuclear and High Energy Physic ,Physics ,Jet (fluid) ,Neutron stimulated emission computed tomography ,Gamma ray ,Molecular ,neutron emission spectrometry ,velocity-space tomography ,Condensed Matter Physics ,Physics::Accelerator Physics ,Atomic physics ,Ion cyclotron resonance - Abstract
© 2017 Technical University of Denmark. We demonstrate the measurement of a 2D MeV-range ion velocity distribution function by velocity-space tomography at JET. Deuterium ions were accelerated into the MeV-range by third harmonic ion cyclotron resonance heating. We made measurements with three neutron emission spectrometers and a high-resolution γ-ray spectrometer detecting the γ-rays released in two reactions. The tomographic inversion based on these five spectra is in excellent agreement with numerical simulations with the ASCOT-RFOF and the SPOT-RFOF codes. The length of the measured fast-ion tail corroborates the prediction that very few particles are accelerated above 2 MeV due to the weak wave-particle interaction at higher energies.
- Published
- 2017
- Full Text
- View/download PDF
13. P09.14 The National Institute of Health stroke scale (NIH-SS) does not predict RANO-MRI findings in the follow up assessment of glioma patients: a monocentric, retrospective analysis
- Author
-
Tobe, V., primary, Desax, M., additional, Sauter, R., additional, Hollenstein, M., additional, Putora, P. M., additional, and Hundsberger, T., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Systematische Entwicklung und Validierung einer Informationsbroschüre zur Harnleiterschienung und der assoziierten Morbidität
- Author
-
Abt, D, Betschart, P, Zumstein, V, Babst, C, Sauter, R, Schmid, HP, Staubli, S, Abt, D, Betschart, P, Zumstein, V, Babst, C, Sauter, R, Schmid, HP, and Staubli, S
- Published
- 2017
15. Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability
- Author
-
Bekes, I., additional, Haunerdinger, V., additional, Sauter, R., additional, Holzheu, I., additional, Janni, W., additional, Wöckel, A., additional, and Wulff, C., additional
- Published
- 2017
- Full Text
- View/download PDF
16. Faking Ability: Measurement and Validity
- Author
-
Geiger, M., primary, Sauter, R., additional, Olderbak, S., additional, and Wilhelm, O., additional
- Published
- 2016
- Full Text
- View/download PDF
17. Disassembling Faking Personality – Towards a Deeper Understanding of the Ability to Fake Personality in Questionnaires and its Covariates
- Author
-
Geiger, M., primary, Sauter, R., additional, Olderbak, S., additional, and Wilhelm, O., additional
- Published
- 2016
- Full Text
- View/download PDF
18. SAT0067 Radiographic Damage and Disability in Patients with Ra in Relation To Disease Duration in The Era of Biologics. Long-Term Results from The SCQM Cohort
- Author
-
Heinimann, K.A., primary, von Kempis, J., additional, Sauter, R., additional, Schiff, M., additional, Schulze-Koops, H., additional, and Mueller, R., additional
- Published
- 2016
- Full Text
- View/download PDF
19. 1041 Economic aspects of morbidity caused by ureteral stents
- Author
-
Abt, D., primary, Staubli, S.E., additional, Mordasini, L., additional, Engeler, D.S., additional, Sauter, R., additional, and Schmid, H-P., additional
- Published
- 2016
- Full Text
- View/download PDF
20. GEMCAT-a new algorithm for gene expression-based prediction of metabolic alterations.
- Author
-
Sharma S, Sauter R, Hotze M, Prowatke AMP, Niere M, Kipura T, Egger AS, Thedieck K, Kwiatkowski M, Ziegler M, and Heiland I
- Subjects
- Humans, Animals, Rats, Proteomics methods, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases metabolism, Transcriptome, Gene Expression Profiling methods, Cell Line, Algorithms, Metabolomics methods
- Abstract
The interpretation of multi-omics datasets obtained from high-throughput approaches is important to understand disease-related physiological changes and to predict biomarkers in body fluids. We present a new metabolite-centred genome-scale metabolic modelling algorithm, the Gene Expression-based Metabolite Centrality Analysis Tool (GEMCAT). GEMCAT enables integration of transcriptomics or proteomics data to predict changes in metabolite concentrations, which can be verified by targeted metabolomics. In addition, GEMCAT allows to trace measured and predicted metabolic changes back to the underlying alterations in gene expression or proteomics and thus enables functional interpretation and integration of multi-omics data. We demonstrate the predictive capacity of GEMCAT on three datasets and genome-scale metabolic networks from two different organisms: (i) we integrated transcriptomics and metabolomics data from an engineered human cell line with a functional deletion of the mitochondrial NAD transporter; (ii) we used a large multi-tissue multi-omics dataset from rats for transcriptome- and proteome-based prediction and verification of training-induced metabolic changes and achieved an average prediction accuracy of 70%; and (iii) we used proteomics measurements from patients with inflammatory bowel disease and verified the predicted changes using metabolomics data from the same patients. For this dataset, the prediction accuracy achieved by GEMCAT was 79%., Competing Interests: None declared., (© The Author(s) 2025. Published by Oxford University Press on behalf of NAR Genomics and Bioinformatics.)
- Published
- 2025
- Full Text
- View/download PDF
21. Association of risk assessment at diagnosis with healthcare resource utilization and health-related quality of life outcomes in pulmonary arterial hypertension.
- Author
-
Lawrie A, Hamilton N, Wood S, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R, Pillai N, and Kiely DG
- Abstract
We aimed to describe the clinical characteristics, healthcare resource utilization (HCRU) and costs, health-related quality of life (HRQoL), and survival for patients with pulmonary arterial hypertension (PAH), stratified by 1-year mortality risk at diagnosis. Adults diagnosed with PAH at the Sheffield Pulmonary Vascular Disease Unit between 2012 and 2019 were included. Patients were categorized as low, intermediate, or high risk for 1-year mortality at diagnosis. Demographics, clinical characteristics, comorbidities, HCRU, costs, HRQoL, and survival were analyzed. Overall, 1717 patients were included: 72 (5%) at low risk, 941 (62%) at intermediate risk, and 496 (33%) at high risk. Low-risk patients had lower HCRU prediagnosis and 1-year postdiagnosis than intermediate- or high-risk patients. Postdiagnosis, there were significant changes in HCRU, particularly inpatient hospitalizations and accident and emergency (A&E) visits among high-risk patients. At 3 years postdiagnosis, HCRU for all measures was similar across risk groups. Low-risk patients had lower EmPHasis-10 scores (indicating better HRQoL) at diagnosis and at 1-year follow-up compared with intermediate- and high-risk patients; only the score in the high-risk group improved. Median overall survival decreased as risk category increased in analyzed subgroups. Low-risk status was associated with better 1-year survival and HRQoL compared with intermediate- and high-risk patients. HCRU decreased in high-risk patients postdiagnosis, with the most marked reduction in A&E admissions. The pattern of decreased per-patient inpatient hospitalizations and A&E visits at 3 years postdiagnosis suggests that a diagnosis of PAH helps to decrease HCRU in areas that are key drivers of costs., Competing Interests: Allan Lawrie is supported by a British Heart Foundation Senior Basic Science Research Fellowship (FS/18/52/33808) and has received honoraria and funding from Janssen Pharmaceuticals to attend scientific meetings. Amélie Beaudet, Audrey Muller, Rafael Sauter, and Nadia Pillai are employees of Actelion Pharmaceuticals Ltd. Amélie Beaudet and Audrey Muller own stock in Johnson & Johnson. Neil Hamilton has received honoraria payments from Janssen Pharmaceuticals, Vifor Pharmaceuticals, and MSD. David G. Kiely has received grants from Janssen Pharmaceuticals and Ferrer; consulting fees from Janssen Pharmaceuticals, MSD, Ferrer, Altavant, and United Therapeutics; honoraria from Janssen Pharmaceuticals, MSD, Ferrer, and United Therapeutics; funding from Janssen Pharmaceuticals, MSD, and Ferrer to attend scientific meetings; has participated in a Data Safety Monitoring Board or Advisory Board for Janssen Pharmaceuticals and MSD; serves on the Specialist Respiratory Clinical Reference Group (unpaid) and as the UK National Audit Chair. Steven Wood has received grants from Janssen Pharmaceuticals in support of the current study. The remaining authors declare no conflict of interest., (© 2024 Actelion Pharmaceuticals Ltd and The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)
- Published
- 2024
- Full Text
- View/download PDF
22. Accounting for NAD Concentrations in Genome-Scale Metabolic Models Captures Important Metabolic Alterations in NAD-Depleted Systems.
- Author
-
Sauter R, Sharma S, and Heiland I
- Subjects
- Humans, Oxidative Phosphorylation, Fatty Acids metabolism, Energy Metabolism, NAD metabolism, Models, Biological, Glycolysis
- Abstract
Nicotinamide adenine dinucleotide (NAD) is a ubiquitous molecule found within all cells, acting as a crucial coenzyme in numerous metabolic reactions. It plays a vital role in energy metabolism, cellular signaling, and DNA repair. Notably, NAD levels decline naturally with age, and this decline is associated with the development of various age-related diseases. Despite this established link, current genome-scale metabolic models, which offer powerful tools for understanding cellular metabolism, do not account for the dynamic changes in NAD concentration. This impedes our understanding of a fluctuating NAD level's impact on cellular metabolism and its contribution to age-related pathologies. To bridge this gap in our knowledge, we have devised a novel method that integrates altered NAD concentration into genome-scale models of human metabolism. This approach allows us to accurately reflect the changes in fatty acid metabolism, glycolysis, and oxidative phosphorylation observed experimentally in an engineered human cell line with a compromised level of subcellular NAD.
- Published
- 2024
- Full Text
- View/download PDF
23. Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service.
- Author
-
Kiely DG, Hamilton N, Wood S, Durrington C, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R, Pillai N, and Lawrie A
- Subjects
- Adult, Humans, Retrospective Studies, Quality of Life, Risk Assessment, United Kingdom epidemiology, Chronic Disease, Hypertension, Pulmonary diagnosis, Pulmonary Embolism complications, Pulmonary Embolism surgery, Pulmonary Embolism diagnosis
- Abstract
Objectives: This study was conducted to evaluate the ability of risk assessment to predict healthcare resource utilisation (HCRU), costs, treatments, health-related quality of life (HRQoL) and survival in patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH)., Design: Retrospective observational study., Setting: Pulmonary hypertension referral centre in the UK., Participants: Adults diagnosed with CTEPH between 1 January 2012 and 30 June 2019 were included. Cohorts were retrospectively defined for operated patients (received pulmonary endarterectomy (PEA)) and not operated; further subgroups were defined based on risk score (low, intermediate or high risk for 1-year mortality) at diagnosis., Primary and Secondary Outcome Measures: Demographics, clinical characteristics, comorbidities, treatment patterns, HRQoL, HCRU, costs and survival outcomes were analysed., Results: Overall, 683 patients were analysed (268 (39%) operated; 415 (61%) not operated). Most patients in the operated and not-operated cohorts were intermediate risk (63%; 53%) or high risk (23%; 31%) at diagnosis. Intermediate-risk and high-risk patients had higher HCRU and costs than low-risk patients. Outpatient and accident and emergency visits were lower postdiagnosis for both cohorts and all risk groups versus prediagnosis. HRQoL scores noticeably improved in the operated cohort post-PEA, and less so in the not-operated cohort at 6-18 months postdiagnosis. Survival at 5 years was 83% (operated) and 49% (not operated) and was lower for intermediate-risk and high-risk patients compared with low-risk patients., Conclusions: Findings from this study support that risk assessment at diagnosis is prognostic for mortality in patients with CTEPH. Low-risk patients have better survival and HRQoL and lower HCRU and costs compared with intermediate-risk and high-risk patients., Competing Interests: Competing interests: DGK has received grants from Janssen Pharmaceuticals and Ferrer; consulting fees from Janssen Pharmaceuticals, MSD, Ferrer, Altavant and United Therapeutics; honoraria from Janssen Pharmaceuticals, MSD, Ferrer and United Therapeutics; funding from Janssen Pharmaceuticals, MSD and Ferrer to attend scientific meetings; has participated in a data safety monitoring board or Advisory Board for Janssen Pharmaceuticals and MSD; serves on the Specialist Respiratory Clinical Reference Group (unpaid) and as the UK National Audit Chair. NH has received honoraria payments from Janssen Pharmaceuticals, Vifor Pharmaceuticals and MSD. SW has received grants from Janssen Pharmaceuticals in support of the current study. CD has received a grant from Janssen, UK for investigator-led research unrelated to the present research, and a speaker’s honorarium from Janssen for an educational lecture. FE, LR and RM have no conflicts to disclose. AB, AM, RS and NP are employees of Actelion Pharmaceuticals. AB, AM and NP own stock in Johnson & Johnson. AL is supported by a British Heart Foundation Senior Basic Science Research Fellowship (FS/18/52/33808)., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
24. Improved mid-term stability of MR reduction with an increased number of clips after percutaneous mitral valve repair in functional MR.
- Author
-
Sauter R, Lin C, Magunia H, Schreieck J, Dürschmied D, Gawaz M, Patzelt J, and Langer HF
- Abstract
Background: Percutaneous mitral valve repair (PMVR) has evolved to be a standard procedure in suitable patients with mitral regurgitation (MR) not accessible for open surgery. Here, we analyzed the influence of the number and positioning of the clips implanted during the procedure on MR reduction analyzing also sub-collectives of functional and degenerative MR (DMR)., Results: We included 410 patients with severe MR undergoing PMVR using the MitraClip® System. MR and reduction of MR were analyzed by TEE at the beginning and at the end of the PMVR procedure. To specify the clip localization, we sub-divided segment 2 into 3 sub-segments using the segmental classification of the mitral valve., Results: We found an enhanced reduction of MR predominantly in DMR patients who received more than one clip. Implantation of only one clip led to a higher MR reduction in patients with functional MR (FMR) in comparison to patients with DMR. No significant differences concerning pressure gradients could be observed in degenerative MR patients regardless of the number of clips implanted. A deterioration of half a grade of the achieved MR reduction was observed 6 months post-PMVR independent of the number of implanted clips with a better stability in FMR patients, who got 3 clips compared to patients with only one clip., Conclusions: In patients with FMR, after 6 months the reduction of MR was more stable with an increased number of implanted clips, which suggests that this specific patient collective may benefit from a higher number of clips., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
25. Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study.
- Author
-
Probert WJM, Sauter R, Pickles M, Cori A, Bell-Mandla NF, Bwalya J, Abeler-Dörner L, Bock P, Donnell DJ, Floyd S, Macleod D, Piwowar-Manning E, Skalland T, Shanaube K, Wilson E, Yang B, Ayles H, Fidler S, Hayes RJ, and Fraser C
- Subjects
- Humans, Bayes Theorem, South Africa epidemiology, Zambia epidemiology, Epidemics prevention & control, HIV Infections diagnosis, HIV Infections drug therapy, HIV Infections epidemiology
- Abstract
Background: The long-term impact of universal home-based testing and treatment as part of universal testing and treatment (UTT) on HIV incidence is unknown. We made projections using a detailed individual-based model of the effect of the intervention delivered in the HPTN 071 (PopART) cluster-randomised trial., Methods: In this modelling study, we fitted an individual-based model to the HIV epidemic and HIV care cascade in 21 high prevalence communities in Zambia and South Africa that were part of the PopART cluster-randomised trial (intervention period Nov 1, 2013, to Dec 31, 2017). The model represents coverage of home-based testing and counselling by age and sex, delivered as part of the trial, antiretroviral therapy (ART) uptake, and any changes in national guidelines on ART eligibility. In PopART, communities were randomly assigned to one of three arms: arm A received the full PopART intervention for all individuals who tested positive for HIV, arm B received the intervention with ART provided in accordance with national guidelines, and arm C received standard of care. We fitted the model to trial data twice using Approximate Bayesian Computation, once before data unblinding and then again after data unblinding. We compared projections of intervention impact with observed effects, and for four different scenarios of UTT up to Jan 1, 2030 in the study communities., Findings: Compared with standard of care, a 51% (95% credible interval 40-60) reduction in HIV incidence is projected if the trial intervention (arms A and B combined) is continued from 2020 to 2030, over and above a declining trend in HIV incidence under standard of care., Interpretation: A widespread and continued commitment to UTT via home-based testing and counselling can have a substantial effect on HIV incidence in high prevalence communities., Funding: National Institute of Allergy and Infectious Diseases, US President's Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, Bill & Melinda Gates Foundation, National Institute on Drug Abuse, and National Institute of Mental Health., Competing Interests: Declaration of interests AC reports funding from the National Institute for Health and Care Research (NIHR), Sergei Brin Foundation, and US Agency for International Development, and from Pfizer for lecturing. CF reports funding from the US National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the US President's Emergency Plan for AIDS Relief (PEPFAR), International Initiative for Impact Evaluation (3ie), the Bill & Melinda Gates Foundation, the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). DM reports funding from NIH, 3ie, PEPFAR, and the Bill & Melinda Gates Foundation. DJD reports funding from NIH and participation on a DSMB for COVID-19 studies. EP-M reports funding from NIH. HA reports funding from NIH, 3ie, and PEPFAR. MP reports funding from the Bill & Melinda Gates Foundation. SFl reports funding from NIH, 3ie, PEPFAR, and the Bill & Melinda Gates Foundation. TS reports funding from NIAID/NIH. WJMP reports funding from Li Ka Shing Foundation and is a consultant with WHO. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.
- Author
-
Lawrie A, Hamilton N, Wood S, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R, Pillai N, and Kiely DG
- Abstract
A retrospective, observational cohort study was conducted to generate real-world evidence in adult patients diagnosed with sarcoidosis-associated pulmonary hypertension (SAPH) at a referral center in England between 2012 and 2019. Data from the referral center electronic medical record database were linked to the National Health Service Hospital Episode Statistics database to collect and analyze patient demographics, clinical characteristics, comorbidities, treatment patterns, health-related quality of life (HRQoL; assessed using the EmPHasis-10 questionnaire), healthcare resource utilization (HCRU), costs, and survival. Sixty-two patients with SAPH were identified. At diagnosis, 84% were in WHO functional class III and presented with significant pulmonary hemodynamic impairment. Cardiovascular and respiratory comorbidities were commonly reported prediagnosis. Median EmPHasis-10 score at diagnosis was 34, indicative of poor HRQoL. In the 1st year after diagnosis, median (Q1, Q3) per-patient HCRU was 1 (0, 2) all-cause inpatient hospitalizations; 3 (2, 4) same-day hospitalizations; and 9 (6, 11) outpatient consultations. In 24 patients who were hospitalized longer than 1 day in the 1st year after diagnosis, the median duration of hospitalization was 4 days. With a median follow-up of 1.8 years, the median overall survival was 2.9 years. In this cohort of patients with SAPH, poor HRQoL and high HCRU were observed following diagnosis. To our knowledge, this is the first study to report on HRQoL and HCRU in patients with SAPH. More research is needed on treatment options for this population with high unmet needs., Competing Interests: Allan Lawrie is supported by a British Heart Foundation Senior Basic Science Research Fellowship (FS/18/52/33808). Amélie Beaudet, Audrey Muller, Rafael Sauter, and Nadia Pillai are employees of Actelion Pharmaceuticals Ltd. Amélie Beaudet and Audrey Muller own stock in Johnson & Johnson. The remaining authors declare no conflict of interest., (© 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)
- Published
- 2022
- Full Text
- View/download PDF
27. Long-Term Outcome of Non-antireflux Robotic-Assisted Robot-Assisted Laparoscopic Ureter Reimplantation in Ureteral Obstruction.
- Author
-
Bausch K, Sauter R, Subotic S, Halbeisen FS, Seifert HH, and Feicke A
- Subjects
- Humans, Replantation, Retrospective Studies, Treatment Outcome, Laparoscopy, Robotic Surgical Procedures, Robotics, Ureter surgery, Ureteral Obstruction complications, Ureteral Obstruction surgery, Vesico-Ureteral Reflux surgery
- Abstract
Purpose: Although robot-assisted laparoscopic ureter reimplantation (RALUR) is a recognized alternative to open and laparoscopic ureter reimplantation in treating distal ureteral obstruction, there are limited data on long-term efficacy and safety outcomes of non-antireflux RALUR. We assessed patients undergoing RALUR, evaluating operative, functional, and safety determinants. Materials and Methods: All consecutive patients undergoing non-antireflux RALUR between April 2015 and January 2020 were included in this retrospective cohort study. The primary outcome endpoint was recurrent distal ureteral obstruction. Results: Mean follow-up was 41.3 months (95% confidence interval, 33.3-49.2; range 2-82). Among the 26 included patients, none developed recurrent distal ureteral obstruction. Kidney function in terms of serum creatinine level (72.0 μmol/L vs 71.0 μmol/L, p = 0.988) and glomerular filtration rate (92.0 mL/min vs 91.0 mL/min, p = 0.831) was stable between the preoperative period and the last follow-up. Renal pelvis dilatation decreased significantly postoperatively, from grade 2 to grade 0 ( p < 0.001). Most patients (73.1%) remained free from any clinical symptoms of reflux during the follow-up. No recurring urinary tract infections were reported. The rate of postoperative complications (Clavien-Dindo grade ≥II) was 23.1%. All complications resolved without sequelae. Conclusions: Non-antireflux RALUR appears to be safe and effective in the management of distal ureteral obstruction. There was no recurrent ureteral obstruction after RALUR in our cohort during a mean follow-up of more than 3 years. Non-antireflux reimplantation did not seem to have any notable impact on renal function during the follow-up period.
- Published
- 2022
- Full Text
- View/download PDF
28. PopART-IBM, a highly efficient stochastic individual-based simulation model of generalised HIV epidemics developed in the context of the HPTN 071 (PopART) trial.
- Author
-
Pickles M, Cori A, Probert WJM, Sauter R, Hinch R, Fidler S, Ayles H, Bock P, Donnell D, Wilson E, Piwowar-Manning E, Floyd S, Hayes RJ, and Fraser C
- Subjects
- Adolescent, Adult, Aged, Algorithms, Antiretroviral Therapy, Highly Active, Disease Progression, Female, HIV Infections drug therapy, HIV Infections transmission, Humans, Incidence, Male, Middle Aged, Prevalence, Reproducibility of Results, Young Adult, Zambia epidemiology, Computer Simulation, HIV Infections epidemiology, Models, Statistical, Stochastic Processes
- Abstract
Mathematical models are powerful tools in HIV epidemiology, producing quantitative projections of key indicators such as HIV incidence and prevalence. In order to improve the accuracy of predictions, such models need to incorporate a number of behavioural and biological heterogeneities, especially those related to the sexual network within which HIV transmission occurs. An individual-based model, which explicitly models sexual partnerships, is thus often the most natural type of model to choose. In this paper we present PopART-IBM, a computationally efficient individual-based model capable of simulating 50 years of an HIV epidemic in a large, high-prevalence community in under a minute. We show how the model calibrates within a Bayesian inference framework to detailed age- and sex-stratified data from multiple sources on HIV prevalence, awareness of HIV status, ART status, and viral suppression for an HPTN 071 (PopART) study community in Zambia, and present future projections of HIV prevalence and incidence for this community in the absence of trial intervention., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
29. Complement, inflammation and thrombosis.
- Author
-
Rawish E, Sauter M, Sauter R, Nording H, and Langer HF
- Subjects
- Blood Platelets, Complement System Proteins, Humans, Inflammation, Platelet Activation, Thrombosis
- Abstract
A mutual relationship exists between immune activation and mechanisms of thrombus formation. In particular, elements of the innate immune response such as the complement system can modulate platelet activation and subsequently thrombus formation. Several components of the complement system including C3 or the membrane attack complex have been reported to be associated with platelets and become functionally active in the micromilieu of platelet activation. The exact mechanisms how this interplay is regulated and its consequences for tissue inflammation, damage or recovery remain to be defined. This review addresses the current state of knowledge on this topic and puts it into context with diseases featuring both thrombosis and complement activation. LINKED ARTICLES: This article is part of a themed issue on Canonical and non-canonical functions of the complement system in health and disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.14/issuetoc., (© 2021 The British Pharmacological Society.)
- Published
- 2021
- Full Text
- View/download PDF
30. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
- Author
-
Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, and Lang I
- Subjects
- Adult, Antihypertensive Agents therapeutic use, Disease Progression, Double-Blind Method, Female, Follow-Up Studies, Global Health, Humans, Male, Middle Aged, Morbidity trends, Prognosis, Pulmonary Arterial Hypertension drug therapy, Pulmonary Arterial Hypertension epidemiology, Pulmonary Wedge Pressure drug effects, Survival Rate trends, Acetamides therapeutic use, Pulmonary Arterial Hypertension diagnosis, Pulmonary Wedge Pressure physiology, Pyrazines therapeutic use
- Abstract
Background: Early initiation of pulmonary arterial hypertension (PAH) therapies is associated with improved long-term outcomes, yet data on the early use of prostacyclin pathway agents are limited. In these post hoc analyses of the Prostacyclin (PGI
2 ) Receptor Agonist In Pulmonary Arterial Hypertension (GRIPHON) study, the largest randomized controlled trial for PAH to date, the prognostic value of time from diagnosis and its impact on treatment response were examined., Research Question: How does time from diagnosis impact morbidity/mortality events and response to selexipag treatment in patients with PAH?, Study Design and Methods: The GRIPHON study randomly assigned 1,156 patients with PAH to selexipag or placebo treatment. Patients were categorized post hoc into a time from diagnosis of ≤ 6 months and > 6 months at randomization. Hazard ratios (selexipag vs placebo) were calculated for the primary end point of morbidity/mortality by time from diagnosis using Cox proportional hazard models., Results: Time from diagnosis was ≤ 6 months in 34.9% and > 6 months in 65.1% of patients. Time from diagnosis was prognostic of morbidity/mortality, with newly diagnosed patients having a poorer long-term outcome than patients diagnosed for longer. Compared with placebo, selexipag reduced the risk of morbidity/mortality in patients with a time from diagnosis of ≤ 6 months and > 6 months, with a more pronounced effect in newly diagnosed patients (hazard ratio, 0.45 [95% CI, 0.33-0.63] and 0.74 [95% CI, 0.57-0.96], respectively; P = .0219 for interaction)., Interpretation: In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. The benefit of selexipag treatment on disease progression was more pronounced in patients treated earlier than in patients treated later., Trial Registry: ClinicalTrials.gov; No.: NCT01106014; URL: www.clinicaltrials.gov., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
31. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.
- Author
-
Nording H, Baron L, Haberthür D, Emschermann F, Mezger M, Sauter M, Sauter R, Patzelt J, Knoepp K, Nording A, Meusel M, Meyer-Saraei R, Hlushchuk R, Sedding D, Borst O, Eitel I, Karsten CM, Feil R, Pichler B, Erdmann J, Verschoor A, Chavakis E, Chavakis T, von Hundelshausen P, Köhl J, Gawaz M, and Langer HF
- Subjects
- Angiogenesis Inducing Agents, Animals, Complement Activation, Complement C5a, Inflammation, Mice, Mice, Knockout, Receptor, Anaphylatoxin C5a deficiency, Receptors, CXCR3 genetics, Signal Transduction, Blood Platelets metabolism, Platelet Factor 4 metabolism, Receptor, Anaphylatoxin C5a genetics, Receptor, Anaphylatoxin C5a metabolism
- Abstract
Platelets contribute to the regulation of tissue neovascularization, although the specific factors underlying this function are unknown. Here, we identified the complement anaphylatoxin C5a-mediated activation of C5a receptor 1 (C5aR1) on platelets as a negative regulatory mechanism of vessel formation. We showed that platelets expressing C5aR1 exert an inhibitory effect on endothelial cell functions such as migration and 2D and 3D tube formation. Growth factor- and hypoxia-driven vascularization was markedly increased in C5ar1
-/- mice. Platelet-specific deletion of C5aR1 resulted in a proangiogenic phenotype with increased collateralization, capillarization and improved pericyte coverage. Mechanistically, we found that C5a induced preferential release of CXC chemokine ligand 4 (CXCL4, PF4) from platelets as an important antiangiogenic paracrine effector molecule. Interfering with the C5aR1-CXCL4 axis reversed the antiangiogenic effect of platelets both in vitro and in vivo.In conclusion, we identified a mechanism for the control of tissue neovascularization through C5a/C5aR1 axis activation in platelets and subsequent induction of the antiangiogenic factor CXCL4.- Published
- 2021
- Full Text
- View/download PDF
32. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
- Author
-
Thomas R, Probert WJM, Sauter R, Mwenge L, Singh S, Kanema S, Vanqa N, Harper A, Burger R, Cori A, Pickles M, Bell-Mandla N, Yang B, Bwalya J, Phiri M, Shanaube K, Floyd S, Donnell D, Bock P, Ayles H, Fidler S, Hayes RJ, Fraser C, and Hauck K
- Subjects
- Adolescent, Adult, Cost-Benefit Analysis economics, Cost-Benefit Analysis statistics & numerical data, Female, HIV Infections economics, Humans, Male, South Africa, Young Adult, Zambia, Anti-Retroviral Agents economics, Anti-Retroviral Agents therapeutic use, Cost-Benefit Analysis methods, HIV Infections diagnosis, HIV Infections drug therapy, HIV Testing economics, HIV Testing methods
- Abstract
Background: The HPTN 071 (PopART) trial showed that a combination HIV prevention package including universal HIV testing and treatment (UTT) reduced population-level incidence of HIV compared with standard care. However, evidence is scarce on the costs and cost-effectiveness of such an intervention., Methods: Using an individual-based model, we simulated the PopART intervention and standard care with antiretroviral therapy (ART) provided according to national guidelines for the 21 trial communities in Zambia and South Africa (for all individuals aged >14 years), with model parameters and primary cost data collected during the PopART trial and from published sources. Two intervention scenarios were modelled: annual rounds of PopART from 2014 to 2030 (PopART 2014-30; as the UNAIDS Fast-Track target year) and three rounds of PopART throughout the trial intervention period (PopART 2014-17). For each country, we calculated incremental cost-effectiveness ratios (ICERs) as the cost per disability-adjusted life-year (DALY) and cost per HIV infection averted. Cost-effectiveness acceptability curves were used to indicate the probability of PopART being cost-effective compared with standard care at different thresholds of cost per DALY averted. We also assessed budget impact by projecting undiscounted costs of the intervention compared with standard care up to 2030., Findings: During 2014-17, the mean cost per person per year of delivering home-based HIV counselling and testing, linkage to care, promotion of ART adherence, and voluntary medical male circumcision via community HIV care providers for the simulated population was US$6·53 (SD 0·29) in Zambia and US$7·93 (0·16) in South Africa. In the PopART 2014-30 scenario, median ICERs for PopART delivered annually until 2030 were $2111 (95% credible interval [CrI] 1827-2462) per HIV infection averted in Zambia and $3248 (2472-3963) per HIV infection averted in South Africa; and $593 (95% CrI 526-674) per DALY averted in Zambia and $645 (538-757) per DALY averted in South Africa. In the PopART 2014-17 scenario, PopART averted one infection at a cost of $1318 (1098-1591) in Zambia and $2236 (1601-2916) in South Africa, and averted one DALY at $258 (225-298) in Zambia and $326 (266-391) in South Africa, when outcomes were projected until 2030. The intervention had almost 100% probability of being cost-effective at thresholds greater than $700 per DALY averted in Zambia, and greater than $800 per DALY averted in South Africa, in the PopART 2014-30 scenario. Incremental programme costs for annual rounds until 2030 were $46·12 million (for a mean of 341 323 people) in Zambia and $30·24 million (for a mean of 165 852 people) in South Africa., Interpretation: Combination prevention with universal home-based testing can be delivered at low annual cost per person but accumulates to a considerable amount when scaled for a growing population. Combination prevention including UTT is cost-effective at thresholds greater than $800 per DALY averted and can be an efficient strategy to reduce HIV incidence in high-prevalence settings., Funding: US National Institutes of Health, President's Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, Bill & Melinda Gates Foundation., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Building Blocks for Magnon Optics: Emission and Conversion of Short Spin Waves.
- Author
-
Groß F, Zelent M, Träger N, Förster J, Sanli UT, Sauter R, Decker M, Back CH, Weigand M, Keskinbora K, Schütz G, Krawczyk M, and Gräfe J
- Abstract
Magnons have proven to be a promising candidate for low-power wave-based computing. The ability to encode information not only in amplitude but also in phase allows for increased data transmission rates. However, efficiently exciting nanoscale spin waves for a functional device requires sophisticated lithography techniques and therefore, remains a challenge. Here, we report on a method to measure the full spin wave isofrequency contour for a given frequency and field. A single antidot within a continuous thin film excites wave vectors along all directions within a single excitation geometry. Varying structural parameters or introducing Dzyaloshinskii-Moriya interaction allows the manipulation and control of the isofrequency contour, which is desirable for the fabrication of future magnonic devices. Additionally, the same antidot structure is utilized as a multipurpose spin wave device. Depending on its position with respect to the microstrip antenna, it can either be an emitter for short spin waves or a directional converter for incoming plane waves. Using simulations we show that such a converter structure is capable of generating a coherent spin wave beam. By introducing a short wavelength spin wave beam into existing magnonic gate logic, it is conceivable to reduce the size of devices to the micrometer scale. This method gives access to short wavelength spin waves to a broad range of magnonic devices without the need for refined sample preparation techniques. The presented toolbox for spin wave manipulation, emission, and conversion is a crucial step for spin wave optics and gate logic.
- Published
- 2020
- Full Text
- View/download PDF
34. Improving Patient Education Materials: A Practical Algorithm from Development to Validation.
- Author
-
Betschart P, Staubli SE, Zumstein V, Babst C, Sauter R, Schmid HP, and Abt D
- Abstract
Objectives: To generate an algorithm for systematic development and validation of written patient information in accordance with well-established and validated psychometric and statistical methods that can be applied to different fields of medicine., Methods: A literature search was carried out in PubMed and Google Scholar. Methods were selected and combined to an algorithm. Feasibility and practicability is tested by the development of patient education materials on "ureteral stenting"., Results: The algorithm includes 4 study phases. After internal audit expert, readability of the first version is objectified using the Flesch Reading Ease formula. This draft is tested by a few patients performing semi-structured interviews using " The think aloud method " by Someren et al. Content validity is evaluated by a written survey by external consultants in accordance with Lawshe's " Quantitative approach to content validity ". The final leaflet is developed at a consensus meeting and validated by patients based on the Consumer Information Rating Form. The new algorithm could be tested by the development of patient education materials on "ureteral stenting" as a test run., Conclusion: We developed an algorithm for systematic development and validation of written patient information in accordance with well-established, validated psychometric and statistical methods. This algorithm can be applied to arbitrary fields of medicine., (Copyright © 2019 by S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
35. Platelets and Immune Responses During Thromboinflammation.
- Author
-
Mezger M, Nording H, Sauter R, Graf T, Heim C, von Bubnoff N, Ensminger SM, and Langer HF
- Subjects
- Animals, Bone Marrow, Complement System Proteins immunology, Complement System Proteins metabolism, Humans, Immunity, Innate, Inflammation etiology, Inflammation metabolism, Platelet Activation, Platelet Membrane Glycoproteins metabolism, Protein Binding, Signal Transduction, Thrombopoiesis, Thrombosis etiology, Thrombosis metabolism, Blood Platelets immunology, Blood Platelets metabolism, Disease Susceptibility, Immunity
- Abstract
Besides mediating hemostatic functions, platelets are increasingly recognized as important players of inflammation. Data from experiments in mice and men revealed various intersection points between thrombosis, hemostasis, and inflammation, which are addressed and discussed in this review in detail. One such example is the intrinsic coagulation cascade that is initiated after platelet activation thereby further propagating and re-enforcing wound healing or thrombus formation but also contributing to the pathophysiology of severe diseases. FXII of the intrinsic pathway connects platelet activation with the coagulation cascade during immune reactions. It can activate the contact system thereby either creating an inflammatory state or accelerating inflammation. Recent insights into platelet biology could show that platelets are equipped with complement receptors. Platelets are important for tissue remodeling after injury has been inflicted to the endothelial barrier and to the subendothelial tissue. Thus, platelets are increasingly recognized as more than just cells relevant for bleeding arrest. Future insights into platelet biology are to be expected. This research will potentially offer novel opportunities for therapeutic intervention in diseases featuring platelet abundance.
- Published
- 2019
- Full Text
- View/download PDF
36. Elevated Mitral Valve Pressure Gradient Is Predictive of Long-Term Outcome After Percutaneous Edge-to-Edge Mitral Valve Repair in Patients With Degenerative Mitral Regurgitation ( MR ), But Not in Functional MR.
- Author
-
Patzelt J, Zhang W, Sauter R, Mezger M, Nording H, Ulrich M, Becker A, Patzelt T, Rudolph V, Eitel I, Saad M, Bamberg F, Schlensak C, Gawaz M, Boekstegers P, Schreieck J, Seizer P, and Langer HF
- Subjects
- Aged, Aged, 80 and over, Echocardiography, Female, Heart-Assist Devices, Humans, Kaplan-Meier Estimate, Male, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency etiology, Mitral Valve Insufficiency physiopathology, Mortality, Prognosis, Proportional Hazards Models, Reoperation, Severity of Illness Index, Treatment Outcome, Cardiac Catheterization, Mitral Valve Annuloplasty, Mitral Valve Insufficiency surgery, Pressure
- Abstract
Background This study analyzed the effects on long-term outcome of residual mitral regurgitation ( MR ) and mean mitral valve pressure gradient ( MVPG ) after percutaneous edge-to-edge mitral valve repair using the MitraClip system. Methods and Results Two hundred fifty-five patients who underwent percutaneous edge-to-edge mitral valve repair were analyzed. Kaplan-Meier and Cox regression analyses were performed to evaluate the impact of residual MR and MVPG on clinical outcome. A combined clinical end point (all-cause mortality, MV surgery, redo procedure, implantation of a left ventricular assist device) was used. After percutaneous edge-to-edge mitral valve repair, mean MVPG increased from 1.6±1.0 to 3.1±1.5 mm Hg ( P<0.001). Reduction of MR severity to ≤2+ postintervention was achieved in 98.4% of all patients. In the overall patient cohort, residual MR was predictive of the combined end point while elevated MVPG >4.4 mm Hg was not according to Kaplan-Meier and Cox regression analyses. We then analyzed the cohort with degenerative and that with functional MR separately to account for these different entities. In the cohort with degenerative MR , elevated MVPG was associated with increased occurrence of the primary end point, whereas this was not observed in the cohort with functional MR . Conclusions MVPG >4.4 mm Hg after MitraClip implantation was predictive of clinical outcome in the patient cohort with degenerative MR . In the patient cohort with functional MR , MVPG >4.4 mm Hg was not associated with increased clinical events.
- Published
- 2019
- Full Text
- View/download PDF
37. Role of Renin-Angiotensin-System in Human Breast Cancer Cells: Is There a Difference in Regulation of Angiogenesis between Hormone-Receptor Positive and Negative Breast Cancer Cells?
- Author
-
Herr D, Sauer C, Holzheu I, Sauter R, Janni W, Wöckel A, and Wulff C
- Abstract
Objective This study examined the role of the RAS in human breast cancer cells to question if there are differences between HR-positive and HR-negative cells with regard to regulation of VEGF. Methods Expression of different RAS components in hormone receptor (HR)-positive and HR-negative breast cancer cells was investigated using RT-PCR. Different stimulation protocols with different RAS inhibitors were used to investigate the effect on VEGF expression. Angiotensin II-dependent expression of VEGF was quantified by real time PCR. In addition, the effect of intrinsic RAS was studied performing siRNA knockdown of angiotensinogen (AGT). Statistical analysis were calculated using IBM SPSS Statistics Version 21. Results Expression of AT
1 R, AT2 R, AGT and ACE was shown in HR-positive and HR-negative breast cancer cell lines. Extrinsic stimulation with angiotensin II increased VEGF significantly. After treatment with captopril or AT1 R-inhibitor candesartan, VEGF-expression decreased significantly in HR-positive and HR-negative cell lines. However, inhibition of AT2 R using PD 123,319 did not show any significant changes of VEGF. After prevention of intrinsic angiotensin II, extrinsic angiotensin II as well as the combination with inhibitors of the receptors caused a significant reduction of VEGF. Surprisingly, the overall effect of the RAS after knockdown of AGT revealed a significant increase of VEGF in HR-positive cells at any time while a significant decrease was observed in HR-negative cells after 144 hours incubation. Conclusion The RAS-dependent regulation of VEGF between HR-positive and HR-negative breast cancer cells seems do be different. These findings provide evidence for a possible future therapeutic strategy.- Published
- 2019
- Full Text
- View/download PDF
38. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
- Author
-
Scheidegger O, Leupold D, Sauter R, Findling O, Rösler KM, and Hundsberger T
- Subjects
- Female, Follow-Up Studies, Glycogen Storage Disease Type II physiopathology, Humans, Male, Prospective Studies, Registries, Retrospective Studies, Switzerland, Treatment Outcome, Enzyme Replacement Therapy, Glycogen Storage Disease Type II drug therapy
- Abstract
Introduction: Although not curative, enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase enzyme has shown to be effective in the treatment of late-onset Pompe disease (LOPD). For this potentially life-long treatment, little is known on the clinical effect of cessation and resuming ERT. Due to a Swiss supreme court decision on ERT reimbursement, a temporary stop of ERT occurred in our study population. The aim of this study was to report the 36-months follow-up assessments after resuming ERT., Methods: After resuming ERT, seven patients suffering from genetically and enzymatically confirmed LOPD had periodic, mandatory, prospective assessments of pulmonary function tests, muscle strength summary scores, distances walked in timed walking tests, and patient-reported questionnaires. Data were statistically analyzed for significant differences between time points at ERT cessation, at ERT resuming, and 36 months thereafter., Results: After resuming ERT forced vital capacity (p = 0.007) and distance walked in the 6 min walk test (6-MWT, p = 0.011) significantly increased at 36 months. Compared to before ERT cessation, distance walked in 6-MWT at 36 months still remained significantly lower (p = 0.005). Self-reported scores in the fatigue severity scale significantly declined at 36 months after resuming ERT (p = 0.019). No other functional or reported parameter significantly changed at 36 months after resuming ERT., Conclusions: Our data suggests that long-term interruption of ERT in LOPD may lead to deterioration of clinical meaningful parameters and quality of life. In addition, a clinical restoration after ERT cessation is possible for most of the LOPD patients within a 36 months follow-up.
- Published
- 2018
- Full Text
- View/download PDF
39. The "g" in Faking: Doublethink the Validity of Personality Self-Report Measures for Applicant Selection.
- Author
-
Geiger M, Olderbak S, Sauter R, and Wilhelm O
- Abstract
The meta-analytic finding that faking does not affect the criterion validity of self-report measures in applicant selection suggests cognitive abilities are crucial to fake personality to an expected optimal profile in self-report measures. Previous studies in this field typically focus on how the extent of faking changes self-report measurement. However, the effect of faking ability is rarely considered. In Study 1 ( n = 151), we link two questionnaires, the WSQ and the NEO-PI-R, to use them for later faking ability tasks. With O
∗ NET expert ratings and the linked questionnaires, we establish veridical responses of optimal personality profiles for both questionnaires. Based on this, in Study 2, we develop six faking ability task employing both questionnaires and three common jobs to fake for. To score the tasks, we introduce profile similarity metrics that compare faked response vectors to optimal profile vectors. The faking ability tasks were administered to a community sample ( n = 210) who additionally completed measures of cognitive abilities, namely general mental ability, crystallized intelligence, and interpersonal abilities. For all, based on previous research, it can be argued that they should predict individual differences in faking ability. We establish a measurement model of faking ability and its relation to the other cognitive abilities. Using structural equations modeling, we find the strongest effect for crystallized intelligence and weaker effects for general mental ability and interpersonal abilities, all positively predicting faking ability. We show for the first time that we can measure faking ability with psychometrically sound techniques, establish a confirmatory factor model of faking ability and that it is largely explained by other cognitive abilities. We conclude that research supporting a positive link between self-reported personality and job performance is presumably confounded by cognitive abilities, because they are predictive of both faking self-reported personality and job performance. We recommend researchers to broaden their measurements with assessments of faking ability or other cognitive abilities (besides general mental ability) in research regarding applicant selection.- Published
- 2018
- Full Text
- View/download PDF
40. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort.
- Author
-
Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, and Müller R
- Abstract
Objectives: There is little information on the relation between disease duration, disability and radiographic outcome since the introduction of biologics into the therapy of rheumatoid arthritis (RA). No long -term cohort studies have been conducted on this subject so far. To analyse radiographic damage, disability, and disease activity in RA-patients dependent on disease duration in the Swiss national RA cohort (SCQM)., Methods: The primary outcome was the association between the radiographic destruction, assessed by Ratingen scores, and disease duration. All patients with at least one clinical visit were analysed with polynomial and multiple negative binomial models., Results: The disease duration in the 8678 patients with available radiographs analysed ranged between less than 1 and more than 65 years (median 8.3). Disease duration and radiographic destruction were significantly associated with an average increase of Ratingen scores by 8.3% per year. Apart from disease duration, positive rheumatoid factor was the strongest predictor for radiographic destruction. While DAS28-scores remained stable in patients with a disease duration of more than 5 years (median DAS28 2.8), HAQ-DI scores increased continuously by 0.018 for each additional year., Conclusion: In this RA cohort, patients show a continuous increase of articular destruction and physical disability in parallel with disease duration. Even when nowadays a satisfactory control of disease activity can be achieved in most patients, RA remains a destructive disease leading to joint destruction and physical disability in many patients., Competing Interests: The authors have nothing to disclose that directly or indirectly might affect, or be perceived to affect, the conduct or reporting of the work they have submitted.
- Published
- 2018
- Full Text
- View/download PDF
41. Comparison of Deep Sedation With General Anesthesia in Patients Undergoing Percutaneous Mitral Valve Repair.
- Author
-
Patzelt J, Ulrich M, Magunia H, Sauter R, Droppa M, Jorbenadze R, Becker AS, Walker T, von Bardeleben RS, Grasshoff C, Rosenberger P, Gawaz M, Seizer P, and Langer HF
- Subjects
- Aged, Aged, 80 and over, Anesthetics, Intravenous adverse effects, Echocardiography, Three-Dimensional, Echocardiography, Transesophageal, Exercise Tolerance, Feasibility Studies, Female, Humans, Hypnotics and Sedatives adverse effects, Length of Stay, Male, Middle Aged, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency physiopathology, Norepinephrine administration & dosage, Operative Time, Postoperative Complications etiology, Propofol adverse effects, Recovery of Function, Retrospective Studies, Time Factors, Treatment Outcome, Vasoconstrictor Agents administration & dosage, Walk Test, Anesthesia, General adverse effects, Anesthetics, Intravenous administration & dosage, Cardiac Catheterization adverse effects, Cardiac Catheterization instrumentation, Deep Sedation adverse effects, Hypnotics and Sedatives administration & dosage, Mitral Valve surgery, Mitral Valve Insufficiency surgery, Propofol administration & dosage
- Abstract
Background: Percutaneous edge-to-edge mitral valve repair (PMVR) has become an established treatment option for mitral regurgitation in patients not eligible for surgical repair. Currently, most procedures are performed under general anesthesia (GA). An increasing number of centers, however, are performing the procedure under deep sedation (DS). Here, we compared patients undergoing PMVR with GA or DS., Methods and Results: A total of 271 consecutive patients underwent PMVR at our institution between May 2014 and December 2016. Seventy-two procedures were performed under GA and 199 procedures under DS. We observed that in the DS group, doses of propofol (743±228 mg for GA versus 369±230 mg for DS, P <0.001) and norepinephrine (1.1±1.6 mg for GA versus 0.2±0.3 mg for DS, P <0.001) were significantly lower. Procedure time, fluoroscopy time, and dose area product were significantly higher in the GA group. There was no significant difference between GA and DS with respect to overall bleeding complications, postinterventional pneumonia (4% for GA versus 5% for DS), or C-reactive protein levels (361±351 nmol/L for GA versus 278±239 nmol/L for DS). Significantly fewer patients with DS needed a postinterventional stay in the intensive care unit (96% for GA versus 19% for DS, P <0.001). Importantly, there was no significant difference between DS and GA regarding intrahospital or 6-month mortality., Conclusions: DS for PMVR is safe and feasible. No disadvantages with respect to procedural outcome or complications in comparison to GA were observed. Applying DS may simplify the PMVR procedure., (© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.)
- Published
- 2017
- Full Text
- View/download PDF
42. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
- Author
-
Vehoff J, Haegele-Link S, Humm A, Kaegi G, Mueller SK, Sauter R, Tettenborn BE, and Hundsberger T
- Subjects
- Adolescent, Adult, Blood Pressure drug effects, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting physiopathology, Retrospective Studies, Time Factors, Valsalva Maneuver drug effects, Young Adult, Fingolimod Hydrochloride adverse effects, Heart Diseases chemically induced, Heart Rate drug effects, Immunosuppressive Agents adverse effects, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
The objective is to prospectively investigate short- and mid-term changes of heart rate variability (HRV) in patients with relapsing-remitting multiple sclerosis (RRMS), being started on fingolimod. In this prospective clinical trial, patient (n = 33) with RRMS starting treatment with fingolimod underwent a time-domain-based analysis of HRV (breathing at rest, deep breath, and in response to the Valsalva maneuver) shortly before, 4.5 h and 3 months after first intake. Blood pressure changes after the Valsalva maneuver were used as a marker of the sympathetic noradrenergic system. We used a non-invasive continuous beat-to-beat heart rate and blood pressure monitoring. In addition, the Fatigue Severity Scale and the refined and abbreviated Composite Autonomic Symptom Score were applied. Significant changes in HRV in RRMS patients, following treatment with fingolimod, were detected. After an initial increase in HRV, measured 4.5 h after the first intake of fingolimod, a substantial decrease in HRV occurred within 3 months on continuous treatment. There is a growing body of evidence for short-term cardiovascular side effects in continuous treatment with fingolimod, driven by the ANS. The mechanisms and the clinical relevance of the observed changes in HRV need further evaluation, especially in longer and larger prospective studies.
- Published
- 2017
- Full Text
- View/download PDF
43. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery.
- Author
-
Broglie MA, Stoeckli SJ, Sauter R, Pasche P, Reinhard A, de Leval L, Huber GF, Pezier TF, Soltermann A, Giger R, Arnold A, Dettmer M, Arnoux A, Müller M, Spreitzer S, Lang F, Lutchmaya M, Stauffer E, Espeli V, Martucci F, Bongiovanni M, Foerbs D, and Jochum W
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell virology, Chemoradiotherapy methods, Female, Head and Neck Neoplasms mortality, Head and Neck Neoplasms virology, Humans, Male, Middle Aged, Oropharyngeal Neoplasms mortality, Oropharyngeal Neoplasms pathology, Oropharyngeal Neoplasms virology, Papillomaviridae genetics, Papillomavirus Infections epidemiology, Prognosis, Retrospective Studies, Risk Factors, Squamous Cell Carcinoma of Head and Neck, Survival Rate, Tissue Array Analysis, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy, Oropharyngeal Neoplasms therapy, Papillomavirus Infections complications
- Abstract
Background: Knowledge about prognostic factors in surgically treated patients with oropharyngeal squamous cell carcinoma (SCC) is limited. The purpose of this study was to identify influential factors on survival in a large cohort of patients with surgically treated oropharyngeal SCC., Methods: Retrospective analysis of survival estimates in patients with surgically treated oropharyngeal SCC using tumoral positivity for human papillomavirus (HPV) and risk-of-death categories according to a study from 2010 as stratification factors., Results: The 5-year overall survival (OS) and disease-specific survival (DSS) rates after surgery alone were higher in HPV-associated oropharyngeal SCC (OS 80% vs 62%; P = .01; DSS 92% vs 76%; P = .03). Patients in the low-risk category had higher survival rates (OS 91%; DSS 99%) than patients in the intermediate-risk group (OS 63%; DSS 83%), and high-risk group (OS 61%; DSS 75%)., Conclusion: Nonsmokers with HPV-positive oropharyngeal SCC have a better prognosis than smokers with HPV-positive oropharyngeal SCC and also than patients with HPV-negative tumors when treated by surgery alone., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
44. Endophenotyping in idiopathic adult onset cervical dystonia.
- Author
-
Kägi G, Ruge D, Brugger F, Katschnig P, Sauter R, Fiorio M, Tinazzi M, Rothwell J, and Bhatia KP
- Subjects
- Adult, Aged, Discrimination Learning physiology, Dystonic Disorders diagnosis, Dystonic Disorders physiopathology, Female, Humans, Male, Middle Aged, Photic Stimulation methods, Random Allocation, Young Adult, Endophenotypes, Torticollis diagnosis, Torticollis physiopathology, Touch physiology, Transcranial Magnetic Stimulation methods, Visual Perception physiology
- Abstract
Objective: Idiopathic adult onset cervical dystonia (IAOCD) is considered to be a partially penetrant autosomal dominant genetic condition. Dystonia may result from genetic and environmental factors. In this view, part of the physiology should be an endophenotype stemming from the genetic background. We assessed the most discriminative test to separate patients with IAOCD and healthy controls for further endophenotyping in non-affected 1st degree relatives., Methods: We included patients with IAOCD, their 1st degree relatives and healthy controls. Tests performed: (1) Sensory temporal discrimination (visual, tactile, visuo-tactile), (2) Paired pulse paradigms using transcranial magnetic stimulation (TMS), (3) Mental rotation paradigms., Results: 45 patients with IAOCD, 23 healthy controls and 14 non-affected 1st degree relatives were recruited. Visuo-tactile temporal discrimination separated best between controls and patients as well as between controls and 1st degree relatives. 36% of the latter had an abnormal visuo-tactile temporal discrimination. No difference between patients and healthy controls was found for the other paradigms., Conclusions: Visuo-tactile temporal discrimination separates controls from patients with IAOCD and its 1st degree relatives. 36% of the latter had abnormal visuo-tactile thresholds supporting the role of visuo-tactile temporal discrimination as an endophenotype for IAOCD., Significance: Even though the study was of exploratory design, our findings expand the understanding of endophenotypes in IAOCD., (Copyright © 2017 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
45. Percutaneous Mitral Valve Edge-to-Edge Repair Assisted by Hemodynamic Support Devices: A Case Series of Bailout Procedures.
- Author
-
Seizer P, Schibilsky D, Sauter R, Schreieck J, Lausberg H, Walker T, Gawaz M, Langer HF, and Schlensak C
- Subjects
- Aged, Aged, 80 and over, Female, Heart Valve Prosthesis Implantation methods, Humans, Male, Middle Aged, Treatment Outcome, Cardiac Surgical Procedures, Hemodynamics physiology, Mitral Valve surgery, Mitral Valve Insufficiency surgery
- Published
- 2017
- Full Text
- View/download PDF
46. Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate.
- Author
-
Müllhaupt G, Abt D, Mordasini L, Köhle O, Engeler DS, Lüthi A, Sauter R, Schmid HP, and Schwab C
- Subjects
- Aged, Aged, 80 and over, Breath Tests, Cardiovascular Diseases, Ethanol analysis, Humans, Male, Middle Aged, Postoperative Complications epidemiology, Prospective Studies, Risk Factors, Thulium, Volatilization, Ethanol metabolism, Laser Therapy methods, Prostate surgery, Sodium Chloride metabolism, Therapeutic Irrigation methods
- Abstract
Purpose: To assess the prevalence and extent of irrigation fluid absorption during thulium laser vaporization of the prostate., Material and Methods: Fifty-four patients undergoing thulium laser vaporization of the prostate were prospectively included into the trial at a tertiary referral center. Isotonic saline containing 1% ethanol was used for intraoperative irrigation. Absorption of irrigation fluid was measured periodically during the operation using the expired breath ethanol technique. Among others, intra- and postoperative changes in biochemical and hematological laboratory findings were assessed., Results: Absorption of irrigation fluid was detected in 7 out of 54 (13%) patients with a median absorption volume of 265 mL (227-615). No significant differences of intra- and postoperative blood parameters were observed between absorbers and nonabsorbers. No risk factor (i.e., age, prostate size, surgery duration, applied energy, and amount of irrigation fluid) for the occurrence of fluid absorption could be identified., Conclusion: Absorption of irrigation fluid also occurs during thulium laser vaporization of the prostate and should be kept in mind, especially in patients at a high cardiovascular risk. However, compared with previously assessed resection and vaporization techniques, thulium vaporization might have a favorable safety profile regarding fluid absorption.
- Published
- 2017
- Full Text
- View/download PDF
47. Adaptive prior weighting in generalized regression.
- Author
-
Held L and Sauter R
- Subjects
- Bayes Theorem, Computer Simulation, Cross-Sectional Studies, Data Interpretation, Statistical, Humans, Models, Statistical, Randomized Controlled Trials as Topic, Logistic Models
- Abstract
The prior distribution is a key ingredient in Bayesian inference. Prior information on regression coefficients may come from different sources and may or may not be in conflict with the observed data. Various methods have been proposed to quantify a potential prior-data conflict, such as Box's p-value. However, there are no clear recommendations how to react to possible prior-data conflict in generalized regression models. To address this deficiency, we propose to adaptively weight a prespecified multivariate normal prior distribution on the regression coefficients. To this end, we relate empirical Bayes estimates of prior weight to Box's p-value and propose alternative fully Bayesian approaches. Prior weighting can be done for the joint prior distribution of the regression coefficients or-under prior independence-separately for prespecified blocks of regression coefficients. We outline how the proposed methodology can be implemented using integrated nested Laplace approximations (INLA) and illustrate the applicability with a Bayesian logistic regression model for data from a cross-sectional study. We also provide a simulation study that shows excellent performance of our approach in the case of prior misspecification in terms of root mean squared error and coverage. Supplementary Materials give details on software implementation and code and another application to binary longitudinal data from a randomized clinical trial using a Bayesian generalized linear mixed model., (© 2016, The International Biometric Society.)
- Published
- 2017
- Full Text
- View/download PDF
48. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2 nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
- Author
-
Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, and Driessen C
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bendamustine Hydrochloride adverse effects, Dexamethasone administration & dosage, Humans, Lenalidomide, Middle Aged, Multiple Myeloma complications, Neutropenia chemically induced, Remission Induction methods, Thalidomide administration & dosage, Thalidomide analogs & derivatives, Thrombocytopenia chemically induced, Thrombocytopenia complications, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy, Salvage Therapy methods
- Abstract
The combination of lenalidomide (Revlimid
® , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (VGPR)]. The combination of bendamustine (B), lenalidomide and dexamethasone (BRd) has shown high efficacy in patients with advanced rrMM. However, dose-limiting haematotoxicity restricted its use in extensively pre-treated patient populations. This prospective, multicentre Phase II study evaluated the efficacy and safety of BRd in rrMM patients with one prior line of therapy. Fifty patients were enrolled (median age 68·5 years [range 46-83]) and were treated with B 75 mg/m2 days 1, 2; R 25 mg days 1-21 and d (40/20 mg) days 1, 8, 15 and 22, for 6 28-day induction cycles, followed by 12 cycles with Rd alone. Pegfilgrastim was administered according to protocol-defined criteria. The study aimed to demonstrate a complete response (CR)/VGPR rate of >40% after induction therapy. Of 45 evaluable patients, 23 (51%) achieved a CR/VGPR. Grade 4 neutropenia or thrombocytopenia occurred in 17 (34%) and 8 (16%) of patients, respectively. BRd is a safe and efficacious regimen as a second line treatment for rrMM, leading to high quality responses in a considerable proportion of patients., (© 2016 John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF
49. CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.
- Author
-
Sauter R, Huang R, Ledergerber B, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hoffmann M, Rougemont M, Günthard HF, and Held L
- Subjects
- CD4-CD8 Ratio, Disease Progression, Female, Follow-Up Studies, HIV Infections diagnosis, HIV Infections virology, Humans, Male, Middle Aged, Retrospective Studies, Viral Load, Antiretroviral Therapy, Highly Active methods, CD4-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes pathology, HIV Infections drug therapy, HIV-1 genetics, RNA, Viral analysis
- Abstract
Plasma HIV viral load is related to declining CD4 lymphocytes. The extent to which CD8 cells, in addition to RNA viral load, predict the depletion of CD4 cells is not well characterized so far. We examine if CD8 cell count is a prognostic factor for CD4 cell counts during an HIV infection.A longitudinal analysis is conducted using data from the Swiss HIV cohort study collected between January 2000 and October 2014. Linear mixed regression models were applied to observations from HIV-1-infected treatment naive patients (NAIVE) and cART-treated patients to predict the short-term evolution of CD4 cell counts. For each subgroup, it was quantified to which extent CD8 cell counts or CD4/CD8 ratios are prognostic factors for disease progression.In both subgroups, 2500 NAIVE and 8902 cART patients, past CD4 cells are positively (P < 0.0001) and past viral load is negatively (P < 0.0001) associated with the outcome. Including additionally past CD8 cell counts improves the fit significantly (P < 0.0001) and increases the marginal explained variation 31.7% to 40.7% for the NAIVE and from 44.1% to 50.7% for the cART group. The past CD4/CD8 ratio (instead of the past CD8 level) is positively associated with the outcome, increasing the explained variation further to 41.8% for NAIVE and 51.9% for cART., Competing Interests: The authors have no conflicts of interest to disclose.
- Published
- 2016
- Full Text
- View/download PDF
50. Platelet bound oxLDL shows an inverse correlation with plasma anaphylatoxin C5a in patients with coronary artery disease.
- Author
-
Nording H, Giesser A, Patzelt J, Sauter R, Emschermann F, Stellos K, Gawaz M, and Langer HF
- Subjects
- Humans, P-Selectin metabolism, Platelet Activation, Platelet Aggregation, Protein Binding, Blood Platelets metabolism, Complement C5a immunology, Coronary Artery Disease blood, Coronary Artery Disease immunology, Lipoproteins, LDL metabolism
- Abstract
Both oxidized lipids as well as the complement system contribute to atherothrombosis. The expression of complement receptors correlates with the expression of platelet activation markers, and platelet bound oxidized low-density lipoprotein (oxLDL) modulates platelet function. In the present study, we investigated the relationship of markers of complement activation, the anaphylatoxins C5a and C3a, and oxidized low-density lipoprotein. Two hundred and seven patients with coronary artery disease (CAD) were analyzed in this study. Using enzyme-linked immunosorbent assays, plasma levels of oxLDL, C3a, and C5a were measured. Moreover, we assessed platelet bound oxLDL by flow cytometry. The overall level of C5a in the troponin negative group (stable angina (SA) and unstable angina (UA)) compared to the troponin positive group (non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI)) did not differ significantly (62.7 ± 32.4 ng/ml versus 65.8 ± 40.3 ng/ml). While C5a and C3a showed a significant correlation with each other (r = 0.25, p < 0.001), there was no statistically significant relationship between C3a and platelet bound oxLDL (r = 0.06, p = 0.37). Furthermore, plasma oxLDL did not correlate with either C3a or C5a. However, we observed a moderate, yet significant negative correlation between plasma C5a and platelet bound oxLDL (r = -0.15, p = 0.04). Partial correlation analysis correcting for the presence of acute coronary syndrome (ACS), troponin status or the subgroups SA, UA, NSTEMI, or STEMI did not alter this correlation substantially. Interestingly, flow cytometric analysis of human platelets showed increased expression of C5aR and P-selectin after in vitro stimulation with oxLDL. In conclusion, the complement anaphylatoxin C5a shows an inverse correlation with platelet bound oxLDL. The relationship of oxidized lipids to particular complement components may add to the platelet-lipid interplay in atherogenesis and trigger future clinical and mechanistic studies.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.